



# **Metrics and Quality Measures for Behavioral Health Clinics**

## **Technical Specifications and Resource Manual**

**(Volume 2)**

**April 2016**

# Contents

- Contents ..... 2
- GENERAL APPENDICES ..... 4
  - Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures ..... 5
  - Appendix B. BHC Value Set Directory User Manual ..... 16
  - Appendix C. Guidance for Selecting Sample Sizes for HEDIS® Hybrid Measures ..... 21
  - Appendix D. Definitions of Practitioner Types ..... 23
- APPENDICES FOR SPECIFIC MEASURES ..... 25
  - Appendix ROUT: Routine Care Needs ..... 26
  - Appendix I-EVAL: Time to Initial Evaluation ..... 28
  - Appendix TX-EVAL: Time to Comprehensive Person and Family-Centered Diagnostic and Treatment Planning Evaluation ..... 33
  - Appendix SUIC: Deaths by Suicide ..... 36
  - Appendix DOC.A: Documentation of Current Medications in the Medical Record ..... 37
  - Appendix DOC.B: Documentation of Current Medications in the Medical Record ..... 40
  - Appendix BMI-SF.A: Preventive Care & Screening: Body Mass Index (BMI) Screening & Follow-Up.. 41
  - Appendix BMI-SF.B. Codes Relevant to Preventive Care & Screening: Adult Body Mass Index (BMI) Screening and Follow-Up..... 44
  - Appendix CBP-BH. Controlling High Blood Pressure ..... 45
  - Appendix TSC.A: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention ... 47
  - Appendix TSC.B: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention ... 50
  - Appendix ASC.A: Preventive Care & Screening: Unhealthy Alcohol Use: Screening & Brief Counseling ..... 51
  - Appendix ASC.B: Preventive Care & Screening: Unhealthy Alcohol Use: Screening & Brief Counseling ..... 54
  - Appendix SRA-BH-C: eCQM Flow for Reporting the Suicide Risk Assessment (SRA-BH-C) Measure... 55
  - Appendix SRA-A.A: eCQM Flow for Reporting the Suicide Risk Assessment (SRA-A) Measure ..... 62
  - Appendix SRA-A.B: Major Depressive Disorder (MDD): Suicide Risk Assessment..... 67
  - Appendix SRA-A.C: Major Depressive Disorder (MDD): Suicide Risk Assessment..... 68
  - Appendix CDF-BH.A: Screening for Clinical Depression and Follow-Up Plan ..... 71
  - Appendix CDF-BH.B: Screening for Clinical Depression and Follow-Up Plan..... 75
  - Appendix DEP-REM-12. Depression Remission at Twelve Months ..... 76
  - Appendix HOU: Housing Status ..... 79

|  |     |
|--|-----|
| Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts.....   | 80  |
| Appendix PCR-BH: Plan All-Cause Readmissions Rate .....  | 134 |
| Appendix AMS-BD: Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder.....                              | 136 |
| Appendix SAA-BH: Adherence to Antipsychotics for Individuals with Schizophrenia.....                                     | 140 |
| Appendix ADD-BH: Follow-Up Care for Children Prescribed Attention-Deficit Hyperactivity Disorder (ADHD) Medication ..... | 142 |
| Appendix AMM-BH: Antidepressant Medication Management.....   | 143 |

## **GENERAL APPENDICES**

## Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

The following tables provide the measurement periods for denominators and numerators as well as the continuous enrollment period, where applicable. For the sake of simplicity, examples of measurement periods and measurement years are provided that rely on the calendar year. For CCBHCs, however, the measurement year (and the measurement period) will vary, depending on the demonstration start date, although the measurement year will always be a full 12 month period. For example, a CCBHC measurement year beginning on March 1, 2017 will end on February 28, 2018 and measurement periods will be in relation to that measurement year. To ascertain measurement periods that correspond to potential CCBHC measurement years, please see the last worksheet in the data-reporting templates.

**Table A1. Clinic-Reported Measures – Measurement Period<sup>1</sup>**

| Measure                            | Denominator <sup>2</sup>                            | Numerator   | Continuous Enrollment Period <sup>3</sup> |
|------------------------------------|---|---|---|
| Routine Care Needs (ROUT) (cont'd) | The measurement year and the 6 months before (e.g., | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, | NA  |

<sup>1</sup> For some measures, the measurement period for the numerator, denominator, or continuous enrollment period varies depending on a specified date for each consumer (such as consumer birthdates, prescription or treatment start dates, and discharge dates). The measurement period defined in these tables identifies the full range of possible dates that will be used to calculate the measure for all measure-eligible consumers. Refer to the specification for additional details.

<sup>2</sup> When reporting each measure, states and BHC providers should report the measurement period they used for the denominator (and the numerator) in the applicable “Start Date” and “End Date” fields in Section B of the data-reporting template. Some measures also require states and BHC providers to review utilization or enrollment prior to this period to identify the measure-eligible population. For these measures, two date ranges are included in this table. The first date range should be used to populate the Start Date and End Date fields, while the second date range defines these prior review periods and should not be included in the Start Date and End Date fields. For example, the AMM-BH measure instructs states to identify enrollees with antidepressant prescriptions that started May 1, 2016 – April 30, 2017 (the first date range). However, states will also need to review enrollee medication history for 105 days prior to the start of the index prescription (the second date range). States and BHC providers should enter “May 1, 2016” in the Start Date field and “April 30, 2017” in the End Date field. States should note any deviations to any measurement period (numerator, denominator, continuous enrollment) in Section E (Adherence to Measure Specifications) of the data-reporting template.

<sup>3</sup> Refer to the measure specification for information on allowable gaps in the continuous enrollment period.

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>  | <b>Denominator<sup>2</sup></b>  | <b>Numerator</b>  | <b>Continuous Enrollment Period<sup>3</sup></b> |
|---|---|---|---|
| Routine Care Needs (ROUT) (cont'd)  | July 1, 2016 – Dec. 31, 2017)   | 2017)   |   |
| Time to Initial Evaluation (I-EVAL)   | The measurement year excluding the last 30 days of the measurement year and including the 6 months before (e.g., July 1, 2016 - Dec. 1, 2017) | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                           | NA  |
| Time to Comprehensive Person and Family-Centered Diagnostic and Treatment Planning Evaluation (TX-EVAL) | The measurement year excluding the last 90 days of the measurement year and including the 6 months before (e.g., July 1, 2016 – Oct. 2, 2017) | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                           | NA  |
| Deaths by Suicide (SUIC)  | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                           | NA  |
| Documentation of Current Medications in the Medical Record (DOC)  | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                           | NA  |
| Preventive Care & Screening: Adult Body Mass Index (BMI) Screening & Follow-Up (BMI-SF)                 | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year and the previous 6 months (e.g., Jul. 1, 2016 – Dec. 31, 2017) | NA  |

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>   | <b>Denominator<sup>2</sup></b>   | <b>Numerator</b>   | <b>Continuous Enrollment Period<sup>3</sup></b> |
|--|--|--|---|
| Body Mass Index Assessment for Children/Adolescents (WCC-BH)                           | The measurement year<br>(e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year<br>(e.g., Jan. 1, 2017 – Dec. 31, 2017)                 | The measurement year                            |
| Controlling High Blood Pressure (Adult) (CBP-BH)                                       | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)<br><br>Hypertension diagnosis: Confirm anytime during the enrollee’s history during or before the first 6 months of the measurement year | The measurement year <sup>4</sup><br>(e.g., Jan. 1, 2017 – Dec. 31, 2017)    | The measurement year                            |
| Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention (TSC)     | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | The measurement year and the prior year (e.g., Jan. 1, 2016 – Dec. 31, 2017) | NA  |
| Preventive Care & Screening: Unhealthy Alcohol Use: Screening & Brief Counseling (ASC) | The measurement year<br>(e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year and the prior year (e.g., Jan. 1, 2016 – Dec. 31, 2017) | NA  |

<sup>4</sup> Blood pressure reading must occur after the diagnosis of hypertension was made.

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>   | <b>Denominator<sup>2</sup></b>  | <b>Numerator</b>   | <b>Continuous Enrollment Period<sup>3</sup></b> |
|--|---|--|---|
| Child and Adolescent Major Depressive Disorder: Suicide Risk Assessment (SRA-BH-C) | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | NA  |
| Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (SRA-A)             | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | NA  |
| Screening for Clinical Depression and Follow-Up Plan (CDF-BH)                      | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | NA  |
| Depression Remission at Twelve Months (DEP-REM-12)                                 | The measurement year, starting for each person's individual index date (e.g., Jan. 1, 2017 – Dec. 31, 2017 for index date Jan. 1, 2017) | Begins on the index date for the individual during the measurement year and ends at the point 12 months and 30 days later) (e.g., for index date Jan. 1, 2017, Jan. 1, 2017 – Jan. 30, 2018) | NA  |



**Table A2. State-Reported Measures – Measurement Period<sup>5</sup>**

| <b>Measure</b>                          | <b>Denominator<sup>6</sup></b>   | <b>Numerator</b>   | <b>Continuous Enrollment Period<sup>7</sup></b> |
|---|--|--|---|
| Housing Status (HOU)                    | The measurement year, divided into 2 equal parts (e.g., Jan. 1, 2017 – Jun. 30, 2017 and Jul. 1, 2017 – Dec. 31, 2017) | The measurement year, divided into 2 equal parts (e.g., Jan. 1, 2017 – Jun. 30, 2017 and Jul. 1, 2017 – Dec. 31, 2017) | NA  |
| Suicide Attempts (SU-A)                 | The first 11 months of the measurement year (e.g., Jan. 1, 2017 – Nov. 30, 2017)                                       | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | The measurement year                            |
| Patient Experience of Care Survey (PEC) | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | NA  |

<sup>5</sup> For some measures, the measurement period for the numerator, denominator, or continuous enrollment period varies depending on a specified date for each consumer (such as consumer birthdates, prescription or treatment start dates, and discharge dates). The measurement period defined in these tables identifies the full range of possible dates that will be used to calculate the measure for all measure-eligible consumers. Refer to the specification for additional details.

<sup>6</sup> When reporting each measure, states and BHC providers should report the measurement period they used for the denominator (and the numerator) in the applicable “Start Date” and “End Date” fields in Section B of the data-reporting template. Some measures also require states and BHC providers to review utilization or enrollment prior to this period to identify the measure-eligible population. For these measures, two date ranges are included in this table. The first date range should be used to populate the Start Date and End Date fields, while the second date range defines these prior review periods and should not be included in the Start Date and End Date fields. For example, the AMM-BH measure instructs states to identify enrollees with antidepressant prescriptions that started May 1, 2016 – April 30, 2017 (the first date range). However, states will also need to review enrollee medication history for 105 days prior to the start of the index prescription (the second date range). States and BHC providers should enter “May 1, 2016” in the Start Date field and “April 30, 2017” in the End Date field. States should note any deviations to any measurement period (numerator, denominator, continuous enrollment) in Section E (Adherence to Measure Specifications) of the data-reporting template.

<sup>7</sup> Refer to the measure specification for information on allowable gaps in the continuous enrollment period.

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>   | <b>Denominator<sup>6</sup></b>  | <b>Numerator</b>   | <b>Continuous Enrollment Period<sup>7</sup></b>  |
|--|---|--|--|
| Youth/Family Experience of Care Survey (Y/FEC)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | NA   |
| Follow-Up After Emergency Department Visit for Mental Illness (FUM)  | The measurement year less the last 30 days of the measurement year (e.g., Jan. 1, 2017 – Dec. 1, 2017)                                    | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | Date of emergency department visit through 30 days after the ED visit  |
| Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (FUA)                             | The measurement year less the last 30 days of the measurement year (e.g., Jan. 1, 2017 – Dec. 1, 2017)                                    | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | Date of emergency department visit through 30 days after the ED visit  |
| Plan All-Cause Readmissions Rate (PCR-BH)  | The measurement year, measured from the discharge date, less the last 30 days of the measurement year (e.g., Jan. 1, 2017 – Dec. 1, 2017) | The measurement year (30 days following IHS discharge date) (e.g., Jan. 1, 2017 – Dec. 31, 2017) | 365 days prior to the Index Discharge Date through 30 days after the Index Discharge Date (e.g., (365 days prior to IHS discharge date through 30 days after the IHS discharge date) |
| Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) | The measurement year and the prior year (e.g., Jan. 1, 2016 – Dec. 31, 2017)  | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)  | The measurement year   |

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>   | <b>Denominator</b>  | <b>Numerator</b>  | <b>Continuous Enrollment Period</b>  |
|--|---|---|--|
| Diabetes Care For People With Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) (SMI-PC) | The measurement year and the prior year (e.g., Jan. 1, 2016 – Dec. 31, 2017)                          | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                                       | The measurement year and the prior year                                    |
| Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)                                  | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                                       | The measurement year   |
| Cardiovascular Monitoring For People With Cardiovascular Disease and Schizophrenia (SMC)                   | The measurement year and the prior year (e.g., Jan. 1, 2016 – Dec. 31, 2017)                          | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                                       | The measurement year and the prior year                                    |
| Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder (AMS-BD)                             | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)   | The measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                                       | The measurement year   |
| Adherence to Antipsychotics for Individuals with Schizophrenia (SAA-BH)                                    | Index prescription start date (IPSD) during the measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017) | IPSD during the measurement year (e.g., Jan. 1, 2017 – Dec. 31, 2017)                           | The measurement year   |
| Adult Follow-Up After Hospitalization for Mental Illness (FUH-BH-A) (cont'd)                               | The measurement year measured from the discharge date, less the last 30 days of the measurement       | 7 day follow-up: The measurement year measured from the discharge date through 7 days after the | The measurement year (discharge date through 30 days after discharge date) |

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>   | <b>Denominator</b>   | <b>Numerator</b>  | <b>Continuous Enrollment Period</b>  |
|--|--|---|--|
| Adult Follow-Up After Hospitalization for Mental Illness (FUH-BH-A) (cont'd) | year (e.g., Jan. 1, 2017 – Dec. 1, 2017)   | <p>discharge date (e.g., January 1, 2017 – December 8, 2017)</p> <p>30 day follow-up: The measurement year measured from the discharge date through 30 days after discharge date (e.g., Jan. 1, 2017 – Dec. 31, 2017)</p>   |  |
| Child Follow-Up After Hospitalization for Mental Illness (FUH-BH-C)          | The measurement year measured from the discharge date, less the last 30 days of the measurement year (e.g., Jan. 1, 2017 – Dec. 1, 2017) | <p>7 day follow-up: The measurement year measured from the discharge date through 7 days after the discharge date (e.g., January 1, 2017 – December 8, 2017)</p> <p>30 day follow-up: The measurement year measured from the discharge date through 30 days after discharge date (e.g., Jan. 1, 2017 – Dec. 31, 2017)</p> | The measurement year (discharge date through 30 days after discharge date) |

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>  | <b>Denominator</b>   | <b>Numerator</b>  | <b>Continuous Enrollment Period</b>  |
|---|--|---|--|
| <p>Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication (ADD-BH)</p> | <p>For the denominator, two measurement periods are used:</p> <p>Index prescription start date (IPSD): 10 months before the measurement year begins to 2 months after the measurement year begins (e.g., March 1, 2016 – February 28, 2017)</p> <p>Negative medication history review: The time period between 120 days before the IPSD measurement period begins and 120 days before the IPSD measurement period ends (e.g., November 2, 2015 – October 31, 2016)</p> | <p>For the numerator, two measurement periods are used:</p> <p>Initiation Phase: The time period between 30 days after the IPSD measurement period begins and 30 days after the IPSD measurement period ends (e.g., March 31, 2016 – March 30, 2017)</p> <p>Continuation and Maintenance Phase: The time period between 300 days after the IPSD measurement period begins and 300 days after the IPSD measurement period ends (e.g., December 26, 2016 – December 25, 2017)</p> | <p>Initiation Phase: 120 days (4 months) prior to the IPSD through 30 days (1 month) after the IPSD<br/>(e.g., November 1, 2015 – March 30, 2017)</p> <p>Continuation Phase: 120 days prior to IPSD through 300 days after the IPSD<br/>(e.g., November 1, 2015 – December 25, 2017)</p> |
| <p>Antidepressant Medication Management (AMM-BH) (cont'd)</p>   | <p>For the denominator, two measurement periods are used:</p> <p>Index prescription start date (IPSD): The time period</p>   | <p>For the numerator, two measurement periods are used:</p> <p>Acute Phase: The time period between 114 days</p>  | <p>105 days (3 months) prior to the IPSD through 231 days after the IPSD<br/>(e.g., Jan. 16, 2016 – Dec. 17, 2017)</p>   |

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>  | <b>Denominator</b>  | <b>Numerator</b>   | <b>Continuous Enrollment Period</b>   |
|---|---|--|---|
| <p>Antidepressant Medication Management (AMM-BH) (cont'd)</p>   | <p>between 7 months before the measurement year begins and 4 months after the measurement year begins (e.g., June 1, 2016 – April 30, 2017)</p> <p>Negative medication history review: The time period between 105 days before the IPSD measurement period begins and 105 days before the IPSD measurement period ends (e.g., February 17, 2016 – January 15, 2017)</p> | <p>after the IPSD measurement period begins and 114 days after the IPSD measurement period ends (e.g., September 23, 2016 – August 22, 2017)</p> <p>Continuation Phase: The time period between 231 days after the IPSD measurement period begins and 231 days after the IPSD measurement period ends (e.g., January 18, 2017 – December 17, 2017)</p> |   |
| <p>Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET-BH) (cont'd)</p> | <p>For the denominator, two measurement periods are used:</p> <p>The Index Episode Start Date (IESD) measurement period is the first 10 months and 15 days of the measurement year. (e.g., Jan. 1, 2017 – Nov. 15, 2017)</p>  | <p>For the numerator, two measurement periods are used:</p> <p>The Initiation of AOD Treatment measurement period covers the 13 days following the IESD. It begins on the 1<sup>st</sup> day of the first month and ends 13 days after the measurement</p>   | <p>60 days (2 months) prior to the IESD through 44 days after the IESD (105 total days)</p> <p>(e.g., Nov. 1, 2016 – Dec. 29, 2017)</p> |

Appendix A. Measurement Period for Denominators and Numerators for the BHC Metrics and Quality Measures

| <b>Measure</b>  | <b>Denominator</b>   | <b>Numerator</b>   | <b>Continuous Enrollment Period</b> |
|---|--|--|-------------------------------------|
| Alcohol and Other Drug (AOD) Dependence Treatment (IET-BH) (cont'd) | The Negative Diagnosis History Review measurement period looks back 60 days prior to the IESD. It begins 60 days prior to the measurement year and ends 60 days prior to the last possible date of the IESD during the measurement year. (e.g., Nov. 2, 2016 – Sept. 16, 2017) | <p>period for the IESD ends. (e.g., Jan. 1, 2017 – Nov. 28, 2017)</p> <p>The Engagement of AOD Treatment measurement period covers the 29 days following Initiation of AOD Treatment. It begins on the 2nd day of the first month and ends 29 days after the measurement period for Initiation. (e.g., Jan. 2, 2017 – Dec. 27, 2017)</p> |                                     |

## Appendix B. BHC Value Set Directory User Manual

### A. What Is the Value Set Directory?

Many measure specifications, including those for HEDIS® measures, reference value sets. A “value set” is the complete set of codes used to identify a service or condition included in a measure. The BHC Value Set Directory (VSD) includes all value sets and codes needed to report many of the BHC measures. This appendix is based upon one written for the HEDIS measures that are part of the CMS Child or Adult Core Sets for Medicaid/CHIP and describes how to use value sets in calculating measures in the BHC set, including for non-HEDIS measures.

### B. Structure of the Value Set Directory

The VSD (Excel workbook) contains the following spreadsheets:

- BHC Measures to Value Sets
- BHC Value Sets to Codes

The columns in the value sets are based on those included in the National Library of Medicine Value Set Authority Center (VSAC) standardized value set file. Not all columns will be needed for reporting BHC HEDIS measures, depending on how the state’s information systems are organized. All columns have been included in the value set to preserve consistency with the national standard.

**Note: Due to licensing restrictions NCQA is prohibited from providing an unlocked, editable version of the BHC Value Sets to Codes spreadsheet.**

### C. Measures to Value Sets

The BHC Measures to Value Sets spreadsheet lists value sets by measure and includes the elements in Table B.1.

**Table B.1. Measures to Value Sets**

| Element Name   | Element Description                 |
|----------------|-------------------------------------|
| Measure ID     | The abbreviation for the measure    |
| Measure Name   | The measure name                    |
| Value Set Name | The value set name                  |
| Value Set OID  | Unique identifier for the value set |

Use the BHC Measures to Value Sets spreadsheet to identify all value sets used for a particular measure or to identify all measures that use a specific value set. For example, setting the Measure ID filter to “WCC” demonstrates that the Weight Assessment and Counseling: Body Mass Index Assessment for Children/Adolescents measure uses the following value sets:



| Measure ID | Measure Name  | Value Set Name | Value Set OID                     |
|------------|---|----------------|-----------------------------------|
| WCC-BH     | Weight Assessment and Counseling: Body Mass Index (BMI) Assessment for Children/Adolescents | BMI Percentile | 2.16.840.1.113883.3.464.1004.1038 |
| WCC-BH     | Weight Assessment and Counseling: Body Mass Index (BMI) Assessment for Children/Adolescents | Pregnancy      | 2.16.840.1.113883.3.464.1004.1219 |

Setting the Value Set Name filter to “Pregnancy” identifies the three measures that use the value set.

| Measure ID | Measure Name  | Value Set Name | Value Set OID                     |
|------------|---|----------------|-----------------------------------|
| CBP-BH     | Controlling High Blood Pressure   | Pregnancy      | 2.16.840.1.113883.3.464.1004.1219 |
| PCR-BH     | Plan All-Cause Readmissions   | Pregnancy      | 2.16.840.1.113883.3.464.1004.1219 |
| WCC-BH     | Weight Assessment and Counseling: Body Mass Index Assessment for Children/Adolescents | Pregnancy      | 2.16.840.1.113883.3.464.1004.1219 |

#### D. Value Sets to Codes

The BHC Value Sets to Codes spreadsheet lists the codes included in each value set and includes the elements in Table B.2.

**Table B.2. Value Sets to Codes**

| Element Name      | Element Description   |
|-------------------|---|
| Value Set Name    | The value set name  |
| Value Set OID     | Unique identifier for the value set   |
| Value Set Version | The version date for the value set directory (2015-12-21 for federal fiscal year 2016 reporting)  |
| Code              | The code  |
| Definition        | The code definition<br><i>Note: The definition is not included for Uniform Bill,<sup>2</sup> CPT<sup>3</sup> or the American Dental Association’s Code on Dental Procedures and Nomenclature (CDT) codes due to licensing restrictions.</i> |

| Element Name        | Element Description   |
|---------------------|---|
| Code System         | <p>The code system for the code. Code systems are labeled as:</p> <p>CPT: Current Procedural Terminology</p> <p>HCPCS: Healthcare Common Procedure Coding System Level II</p> <p>ICD-10-CM: International Classification of Diseases, 10th Revision, Clinical Modification (Diagnosis codes)</p> <p>ICD-10-PCS: International Classification of Diseases, 10th Revision, Procedure Coding System (Procedure codes)</p> <p>ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification (Diagnosis codes)</p> <p>ICD-9-PCS: International Classification of Diseases, 9th Revision, Clinical Modification (Procedure codes)</p> <p>POS: CMS Place of Service</p> <p>UBREV: Uniform Bill (Revenue codes)</p> <p>UBTOB: Uniform Bill (Type of Bill codes)</p> |
| Code System OID     | Unique identifier for the code system.  |
| Code System Version | Code system version tracking number.  |

<sup>1</sup>Uniform Bill Codes (“UB Codes”) are protected under federal copyright laws and are owned by the American Hospital Association (AHA). The UB Codes in the HEDIS specifications are included with the permission of the AHA. The UB Codes contained in the HEDIS specifications may be used by health plans and other health care delivery organizations for the purpose of calculating and reporting HEDIS results or using HEDIS measure results for their internal quality improvement purposes. All other uses of the UB Codes require a license from the AHA. Software vendors and all others desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact [ub04@healthforum.com](mailto:ub04@healthforum.com).

<sup>2</sup>CPT codes copyright 2015 American Medical Association. All rights reserved. CPT is a trademark of the AMA. No fee schedules, basic units, relative values or related listings are included in CPT. The AMA assumes no liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.

Appendix B. BHC Value Set Directory User Manual

Use the Value Sets to Codes spreadsheet to identify all codes in a value set or to identify all value sets that use a particular code. For example, setting the Value Set Name filter to “Narcolepsy” demonstrates that the following codes are included in the value set.

| <b>Value Set Name</b> | <b>Value Set OID</b>              | <b>Value Set Version</b> | <b>Code</b> | <b>Definition</b>  | <b>Code System</b> | <b>Code System OID</b>  | <b>Code System Version</b> |
|-----------------------|-----------------------------------|--------------------------|-------------|--|--------------------|-------------------------|----------------------------|
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | 347.01      | Narcolepsy, with cataplexy                                       | ICD-9-CM           | 2.16.840.1.113883.6.103 | 2014.1.13AA                |
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | 347.11      | Narcolepsy in conditions classified elsewhere, with cataplexy    | ICD-9-CM           | 2.16.840.1.113883.6.103 | 2014.1.13AA                |
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | 347.00      | Narcolepsy, without cataplexy                                    | ICD-9-CM           | 2.16.840.1.113883.6.103 | 2014.1.13AA                |
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | 347.10      | Narcolepsy in conditions classified elsewhere, without cataplexy | ICD-9-CM           | 2.16.840.1.113883.6.103 | 2014.1.13AA                |
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | G47.411     | Narcolepsy with cataplexy  | ICD-10-CM          | 2.16.840.1.113883.6.90  | 2014.0.0.13AA              |
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | G47.419     | Narcolepsy without cataplexy                                     | ICD-10-CM          | 2.16.840.1.113883.6.90  | 2014.0.0.13AA              |

| <b>Value Set Name</b> | <b>Value Set OID</b>              | <b>Value Set Version</b> | <b>Code</b> | <b>Definition</b>   | <b>Code System</b> | <b>Code System OID</b> | <b>Code System Version</b> |
|-----------------------|-----------------------------------|--------------------------|-------------|---|--------------------|------------------------|----------------------------|
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | G47.421     | Narcolepsy in conditions classified elsewhere with cataplexy    | ICD-10-CM          | 2.16.840.1.113883.6.90 | 2014.0.0.13AA              |
| Narcolepsy            | 2.16.840.1.113883.3.464.1004.1182 | 2015-12-21               | G47.429     | Narcolepsy in conditions classified elsewhere without cataplexy | ICD-10-CM          | 2.16.840.1.113883.6.90 | 2014.0.0.13AA              |

Setting the Code filter to “002.3” demonstrates that the code is included in the following value set.

| <b>Value Set Name</b> | <b>Value Set OID</b>              | <b>Value Set Version</b> | <b>Code</b> | <b>Definition</b>   | <b>Code System</b> | <b>Code System OID</b>  | <b>Code System Version</b> |
|-----------------------|-----------------------------------|--------------------------|-------------|---------------------|--------------------|-------------------------|----------------------------|
| Acute Condition       | 2.16.840.1.113883.3.464.1004.1324 | 2015-12-21               | 002.3       | Paratyphoid fever C | ICD-9-CM           | 2.16.840.1.113883.6.103 | 2014.1.13AA                |

**Appendix C. Guidance for Selecting Sample Sizes for HEDIS® Hybrid Measures**

This appendix provides additional information on when it may be feasible to use a sample size of less than 411 when the hybrid method is used. The sample size is based on the current year’s administrative rate<sup>8</sup> or the prior years reported rate. The guidance in the table below is designed to minimize the burden of medical record review, while providing an adequate sample size for calculating the measure.

**Table C.1. Determining Sample Sizes for Hybrid Measures when Data Are Available from the Current Year’s Administrative Rate or the Prior Year’s Reported Rate**

| <b>Current Year’s Administrative Rate or the Prior Year’s Reported Rate</b> | <b>Minimum Sample Size</b> |
|---|----------------------------|
| Less than or equal to 50%   | 411                        |
| 51%   | 411                        |
| 52%   | 410                        |
| 53%   | 410                        |
| 54%   | 409                        |
| 55%   | 407                        |
| 56%   | 405                        |
| 57%   | 403                        |
| 58%   | 401                        |
| 59%   | 398                        |
| 60%   | 395                        |
| 61%   | 392                        |
| 62%   | 388                        |
| 63%   | 384                        |
| 64%   | 380                        |
| 65%   | 376                        |
| 66%   | 371                        |
| 67%   | 366                        |

<sup>8</sup> The administrative rate refers to the performance rate that is calculated using administrative data only, rather than from any medical record reviews.

Appendix C. Guidance for Selecting Sample Sizes for HEDIS® Hybrid Measures

| <b>Current Year's Administrative Rate or the Prior Year's Reported Rate</b> | <b>Minimum Sample Size</b> |
|---|----------------------------|
| 68%   | 360                        |
| 69%   | 354                        |
| 70%   | 348                        |
| 71%   | 342                        |
| 72%   | 335                        |
| 73%   | 328                        |
| 74%   | 321                        |
| 75%   | 313                        |
| 76%   | 305                        |
| 77%   | 296                        |
| 78%   | 288                        |
| 79%   | 279                        |
| 80%   | 270                        |
| 81%   | 260                        |
| 82%   | 250                        |
| 83%   | 240                        |
| 84%   | 229                        |
| 85%   | 219                        |
| 86%   | 207                        |
| 87%   | 196                        |
| 88%   | 184                        |
| 89%   | 172                        |
| 90%   | 159                        |
| 91%   | 147                        |
| 92%   | 134                        |
| 93%   | 120                        |
| 94%   | 106                        |
| Greater than or equal to 95%  | 100                        |

Note: Truncate the decimal portion of the rate to obtain a whole number.

## Appendix D. Definitions of Practitioner Types

### Appendix D. Definitions of Practitioner Types

| PRACTITIONER TYPE          | DEFINITION  |
|----------------------------|---|
| Mental Health Practitioner | <p>A practitioner who provides mental health services and meets any of the following criteria:</p> <ul style="list-style-type: none"> <li>• An MD or doctor of osteopathy (DO) who is certified as a psychiatrist or child psychiatrist by the American Medical Specialties Board of Psychiatry and Neurology or by the American Osteopathic Board of Neurology and Psychiatry; or, if not certified, who successfully completed an accredited program of graduate medical or osteopathic education in psychiatry or child psychiatry and is licensed to practice patient care psychiatry or child psychiatry, if required by the state of practice</li> <li>• An individual who is licensed as a psychologist in his/her state of practice, if required by the state of practice</li> <li>• An individual who is certified in clinical social work by the American Board of Examiners; who is listed on the National Association of Social Worker’s Clinical Register; or who has a master’s degree in social work and is licensed or certified to practice as a social worker, if required by the state of practice</li> <li>• A registered nurse (RN) who is certified by the American Nurses Credentialing Center (a subsidiary of the American Nurses Association) as a psychiatric nurse or mental health clinical nurse specialist, or who has a master’s degree in nursing with a specialization in psychiatric/mental health and two years of supervised clinical experience and is licensed to practice as a psychiatric or mental health nurse, if required by the state of practice</li> <li>• An individual (normally with a master’s or a doctoral degree in marital and family therapy and at least two years of supervised clinical experience) who is practicing as a marital and family therapist and is licensed or a certified counselor by the state of practice, or if licensure or certification is not required by the state of practice, who is eligible for clinical membership in the American Association for Marriage and Family Therapy</li> <li>• An individual (normally with a master’s or doctoral degree in counseling and at least two years of supervised clinical experience) who is practicing as a professional counselor and who is licensed or certified to do so by the state of practice, or if licensure or certification is not required by the state of practice, is a National Certified Counselor with Specialty Certification in Clinical Mental Health Counseling from the National Board for Certified Counselors (NBCC)</li> </ul> |

## Appendix D. Definitions of Practitioner Types

| <b>PRACTITIONER TYPE</b>  | <b>DEFINITION</b>   |
|---|---|
| Obstetrical/Gynecological (OB/GYN) and Other Prenatal Care Practitioner | <p>Includes:</p> <ul style="list-style-type: none"> <li>• Physicians certified as obstetricians or gynecologists by the American Medical Specialties Board of Obstetrics or Gynecology or the American Osteopathic Association; or, if not certified, who successfully completed an accredited program of graduate medical or osteopathic education in obstetrics and gynecology</li> <li>• Certified nurse midwives and nurse practitioners who deliver prenatal care services in a specialty setting (under the direction of an OB/GYN certified or accredited provider)</li> </ul> |
| Primary Care Practitioner (PCP)   | <ul style="list-style-type: none"> <li>• A physician or nonphysician (e.g., nurse practitioner, physician assistant) who offers primary care medical services</li> <li>• Licensed practical nurses and registered nurses are not considered PCPs</li> </ul>   |
| Prescribing Practitioner  | A practitioner with prescribing privileges, including nurse practitioners, physician assistants, and other non-MDs who have the authority to prescribe medications  |



## **APPENDICES FOR SPECIFIC MEASURES**

## Appendix ROUT: Routine Care Needs

Percentage of new consumers requesting services who were determined to need routine care

### EXAMPLE

Assuming 10 new consumers during the measurement year (Consumers A through J) with the data shown in the table below, the percentage of new consumers, stratified by payer status, presenting with routine (R) vs non-routine (N) needs is shown on the last line of the table below.

| <b>Consumer</b>                   | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b>    |
|-----------------------------------|-----------------|--------------------------------|----------------|-----------------|
| A                                 | R               |                                |                | R               |
| B                                 |                 | R                              |                | R               |
| C                                 | N               |                                |                | N               |
| D                                 | N               |                                |                | N               |
| E                                 |                 | N                              |                | N               |
| F                                 |                 |                                | N              | N               |
| G                                 | R               |                                |                | R               |
| H                                 | R               |                                |                | R               |
| I                                 |                 | N                              |                | N               |
| J                                 |                 |                                | R              | R               |
| Total                             | 5               | 3                              | 2              | 10              |
| Routine needs                     | 3               | 1                              | 1              | 5               |
| Non-routine needs                 | 2               | 2                              | 1              | 5               |
| <b>Percent with routine needs</b> | <b>3/5=60%</b>  | <b>1/3=33%</b>                 | <b>1/2=50%</b> | <b>5/10=50%</b> |

Metrics interpretation: For the Medicaid eligible population, 60% were identified as having routine needs; 33% of those with both Medicaid and Medicare had routine needs;

## Appendix ROUT: Routine Care Needs

and 50% of those with neither had routine needs. Overall across the eligible population, 50% were identified as having routine needs.

## Appendix I-EVAL: Time to Initial Evaluation

**Metric #1:** The percentage of new consumers with initial evaluation provided within 10 business days of first contact

**Metric #2:** The mean number of days until initial evaluation for new consumers

### EXAMPLES

#### METRIC #1

The percentage of new consumers with initial evaluation provided within 10 business days of first contact:

**Denominator:** Calculate the denominator as follows, with the measurement period being the first 11 months of the measurement year (MY) and the 6 months preceding the MY contact:

1. 100 consumers contact clinic in first 11 months of the MY
2. 50 of those were not seen at the clinic in the 6 months preceding the MY contact
3. Of those 50, 20 were Medicaid eligible, 15 were both Medicare and Medicaid eligible, and 15 were neither.
4. Calculate as follows for stratification by payer:

| Steps in calculation  | Medicaid  | Medicare & Medicaid | Neither   | Total     |
|---|-----------|---------------------|-----------|-----------|
| Number of consumers who contact clinic in first 11 months of the MY             | 50        | 25                  | 25        | 100       |
| Number of those not seen at the clinic in the 6 months preceding the MY contact | 20        | 15                  | 15        | 50        |
| <b>Denominator stratified by payer status</b>                                   | <b>20</b> | <b>15</b>           | <b>15</b> | <b>50</b> |

Appendix I-EVAL: Time to Initial Evaluation

**Numerator:** Calculate the numerator for stratification by payer as follows, with the measurement period being the measurement year (MY):

| <b>Steps in calculation</b>                   | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|---|-----------------|--------------------------------|----------------|--------------|
| Denominator stratified by payer status        | 20              | 15                             | 15             | 50           |
| Seen within 10 business days of first contact | 19              | 10                             | 7              | 36           |
| <b>Numerator stratified by payer status</b>   | <b>19</b>       | <b>10</b>                      | <b>7</b>       | <b>36</b>    |

**Quality Metric, the percentage of new consumers with initial evaluation provided within 10 business days of first contact, by payer status:**

**Medicaid:**  $19/20 = .950 = .95$  or **95%**

**Medicare & Medicaid:**  $10/15 = .667 = .67$  or **67%**

**Neither:**  $7/15 = .467 = .47$  or **47%**

**Total:**  $36/50 = .720 = .72$  or **72%**

Metrics interpretation: For the Medicaid eligible population, 95% received an initial evaluation within 10 days of their initial contact with the BHC; whereas, only 67% of those dually eligible for Medicare and Medicaid and only 47% of consumers without Medicare or Medicaid (referred to as “Neither”) received a similar initial evaluation. Overall, across the eligible population, 72% received an initial evaluation within 10 days of their initial contact with the BHC.

See below for similar calculation stratified by age:

**Denominator:**

| <b>Steps in calculation</b>   | <b>Aged 12-17</b> | <b>Aged 18 and older</b> | <b>Total</b> |
|---|-------------------|--------------------------|--------------|
| Number of consumers who contact clinic in first 11 months of the MY             | 25                | 75                       | 100          |
| Number of those not seen at the clinic in the 6 months preceding the MY contact | 10                | 40                       | 50           |

Appendix I-EVAL: Time to Initial Evaluation

| Steps in calculation          | Aged 12-17 | Aged 18 and older | Total |
|-------------------------------|------------|-------------------|-------|
| Denominator stratified by age | 10         | 40                | 50    |

*Numerator:*

| Steps in calculation                          | Aged 12-17 | Aged 18 and older | Total     |
|---|------------|-------------------|-----------|
| Denominator stratified by age                 | 10         | 40                | 50        |
| Seen within 10 business days of first contact | 3          | 33                | 36        |
| <b>Numerator stratified by age</b>            | <b>3</b>   | <b>33</b>         | <b>36</b> |

*Quality Metric, the percentage of new consumers with initial evaluation provided within 10 business days of first contact, by age category:*

**Aged 12-17 years:**  $3/10 = .300 = .30$  or **30%**

**Aged 18 years and older:**  $33/40 = .825 = .83$  or **83%**

**Total:**  $36/50 = .720 = .72$  or **72%**

Metrics interpretation: For those consumers in the eligible population aged 18 years and older, 83% received an initial evaluation within 10 days of their initial contact with the BHC, compared to 30% of consumers aged 12-17 years of age who received an initial evaluation.

**METRIC #2**

The mean number of days until initial evaluation for new consumers:

Assuming 10 consumers (Consumers A through J) seen during the first 11 months of the measurement year and not seen at the clinic in the prior 6 months with counts by payer status as shown below:

*Denominator:* The number of eligible consumers:

| Number of consumers | Medicaid | Medicare & Medicaid | Neither | Total |
|---------------------|----------|---------------------|---------|-------|
|                     | 4        | 3                   | 3       | 10    |

Appendix I-EVAL: Time to Initial Evaluation

**Numerator:** The total number of business days between first contact and initial evaluation (stratified by payer status):

| <b>Consumer</b>        | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|------------------------|-----------------|--------------------------------|----------------|--------------|
| A                      | 10              |                                |                | 10           |
| B                      | 15              |                                |                | 15           |
| C                      | 8               |                                |                | 8            |
| D                      | 31*             |                                |                | 31*          |
| E                      |                 | 20                             |                | 20           |
| F                      |                 | 13                             |                | 13           |
| G                      |                 | 3                              |                | 3            |
| H                      |                 |                                | 4              | 4            |
| I                      |                 |                                | 3              | 3            |
| J                      |                 |                                | 31*            | 31*          |
| <b>Total Numerator</b> | <b>64</b>       | <b>36</b>                      | <b>38</b>      | <b>138</b>   |

\* First contact at the end of the 11<sup>th</sup> month of the MY and not seen again for initial evaluation.

**Quality Metric, the mean number of days until initial evaluation for new consumers, by payer status:**

**Medicaid:**  $64 / 4 = 16$  days

**Medicare & Medicaid:**  $36 / 3 = 12$  days

**Neither:**  $38 / 3 = 12.7$  days

**Total:**  $138 / 10 = 13.8$  days

Metrics interpretation: For the Medicaid new consumers in the eligible population, an average of 16 days elapsed until initial evaluation; whereas, those consumers who had neither Medicaid or Medicare (referred to as “Neither”) had 12.7 days on average before an initial evaluation.

See below for similar calculation stratified by age:

**Denominator:**

Appendix I-EVAL: Time to Initial Evaluation

| Number of consumers | Aged 12-17 years | Aged 18 years and older | Total |
|---------------------|------------------|-------------------------|-------|
|                     | 3                | 7                       | 10    |

*Numerator:*

| Consumer               | Aged 12-17 years | Aged 18 years and older | Total      |
|------------------------|------------------|-------------------------|------------|
| A                      |                  | 10                      | 10         |
| B                      |                  | 15                      | 15         |
| C                      |                  | 8                       | 8          |
| D                      | 31*              |                         | 31*        |
| E                      |                  | 20                      | 20         |
| F                      |                  | 13                      | 13         |
| G                      |                  | 3                       | 3          |
| H                      | 4                |                         | 4          |
| I                      |                  | 3                       | 3          |
| J                      | 31*              |                         | 31*        |
| <b>Total Numerator</b> | <b>66</b>        | <b>72</b>               | <b>138</b> |

\* First contact at the end of the 11<sup>th</sup> month of the MY and not seen again for initial evaluation.

*Quality Metric, the mean number of days until initial evaluation for new consumers, by age category:*

**Aged 12-17 years:**  $66/3 = 33$  days

**Aged 18 years and older:**  $72/7 = 10.29$  or **10.3** days

**Total:**  $138/10 = 13.8$  days

Metrics interpretation: For the new consumers aged 18 years and older in the eligible population, an average of 10.3 days elapsed until initial evaluation; whereas, those consumers aged 12-17 years had 33 days on average before an initial evaluation.



## Appendix TX-EVAL: Time to Comprehensive Person and Family-Centered Diagnostic and Treatment Planning Evaluation

The mean number of days after first contact until comprehensive person-centered and family centered diagnostic and treatment planning evaluation is performed for new consumers

### EXAMPLE

Assuming 10 consumers (Consumers A through J) seen during the first 9 months of the measurement year and not seen at the clinic in the prior 6 months with counts by payer status as shown below:

*Denominator:* The number of eligible consumers:

| Number of consumers | Medicaid | Medicare & Medicaid | Neither | Total |
|---------------------|----------|---------------------|---------|-------|
|                     | 4        | 3                   | 3       | 10    |

*Numerator:*

The total number of days between first contact and comprehensive evaluation (stratified by payer status):

| Consumer | Medicaid | Medicare & Medicaid | Neither | Total |
|----------|----------|---------------------|---------|-------|
| A        | 100      |                     |         | 100   |
| B        | 150      |                     |         | 150   |
| C        | 40       |                     |         | 40    |
| D        | 91*      |                     |         | 91*   |
| E        |          | 30                  |         | 30    |
| F        |          | 45                  |         | 45    |
| G        |          | 55                  |         | 55    |
| H        |          |                     | 34      | 34    |
| I        |          |                     | 45      | 45    |

Appendix TX-EVAL: Time to Comprehensive Person and Family-Centered Diagnostic and Treatment Planning Evaluation

| Consumer               | Medicaid   | Medicare & Medicaid | Neither    | Total      |
|------------------------|------------|---------------------|------------|------------|
| J                      |            |                     | 91*        | 91*        |
| <b>Total Numerator</b> | <b>381</b> | <b>130</b>          | <b>170</b> | <b>681</b> |

\* First contact at the end of the 9<sup>th</sup> month of the MY and not seen again for comprehensive evaluation.

*Quality Metric, the mean number of days after first contact until comprehensive person-centered and family centered diagnostic and treatment planning evaluation is performed for new consumers, by payer status:*

**Medicaid:**  $381/4 = 95.3$  days

**Medicare & Medicaid:**  $130/3 = 43.3$  days

**Neither:**  $170/3 = 56.7$  days

**Total:**  $681/10 = 68.1$  days

Metrics interpretation: For the Medicaid consumers in the eligible population, on average, 95.3 days elapsed between first contact until comprehensive person-centered and family centered diagnostic and treatment planning evaluation is performed for these new consumers, in contrast to 68.1 days for the total population.

See below for similar calculation stratified by age:

**Denominator:**

| Number of consumers | Aged 12-17 years | Aged 18 years and older | Total |
|---------------------|------------------|-------------------------|-------|
|                     | 3                | 7                       | 10    |

**Numerator:**

| Consumer | Aged 12-17 years | Aged 18 years and older | Total |
|----------|------------------|-------------------------|-------|
| A        |                  | 100                     | 100   |
| B        | 150              |                         | 150   |
| C        |                  | 40                      | 40    |

Appendix TX-EVAL: Time to Comprehensive Person and Family-Centered Diagnostic and Treatment Planning Evaluation

| Consumer               | Aged 12-17 years | Aged 18 years and older | Total      |
|------------------------|------------------|-------------------------|------------|
| D                      |                  | 91*                     | 91*        |
| E                      |                  | 30                      | 30         |
| F                      | 45               |                         | 45         |
| G                      |                  | 55                      | 55         |
| H                      |                  | 34                      | 34         |
| I                      |                  | 45                      | 45         |
| J                      | 91*              |                         | 91*        |
| <b>Total Numerator</b> | <b>286</b>       | <b>395</b>              | <b>681</b> |

\* First contact at the end of the 11<sup>th</sup> month of the MY and not seen again for comprehensive evaluation.

*Quality Metric, the mean number of days after first contact until comprehensive person-centered and family centered diagnostic and treatment planning evaluation is performed for new consumers, by age category:*

**Aged 12-17 years:**  $286/3 = 95.3$  days

**Aged 18 years and older:**  $395/7 = 56.4$  days

**Total:**  $681/10 = 68.1$  days

Metrics interpretation: For the consumers in the eligible population aged 18 years and older, on average, 56.4 days elapsed between first contact until comprehensive person-centered and family centered diagnostic and treatment planning evaluation is performed for these new consumers; whereas, for those consumers aged 12-17 years, over 95 days elapsed between the 2 events.

## Appendix SUIC: Deaths by Suicide

Percentage of consumers aged 12 years and older who died by suicide during the measurement year

### EXAMPLE

Calculate the metric stratified by age as follows:

| Age                | Number of consumers | Number of suicides | Percentage          |
|--------------------|---------------------|--------------------|---------------------|
| 12–17 years        | 60                  | 2                  | $2/60 = .03$ or 3%  |
| 18–64 years        | 100                 | 4                  | $4/100 = .04$ or 4% |
| 65 years and older | 50                  | 2                  | $2/50 = .04$ or 4%  |
| Total              | 210                 | 8                  | $8/210 = .04$ or 4% |

Metrics interpretation: Consumers ages 12-17 had the lowest rate of deaths by suicide (3% in contrast to 4% for the rest of the population).

Calculate the metric stratified by payer status as follows:

| Payer status          | Number of consumers | Number of suicides | Percentage          |
|-----------------------|---------------------|--------------------|---------------------|
| Medicaid only         | 100                 | 4                  | $4/100 = .04$ or 4% |
| Medicare and Medicaid | 70                  | 3                  | $3/70 = .04$ or 4%  |
| Neither               | 40                  | 1                  | $1/40 = .03$ or 3%  |
| Total                 | 210                 | 8                  | $8/210 = .04$ or 4% |

Metrics interpretation: Consumers who had neither Medicaid nor dual eligibility for Medicare and Medicaid had the lowest rate of deaths by suicide (3% in contrast to 4% for all other payer groups).

## **Appendix DOC.A: Documentation of Current Medications in the Medical Record**

Percentage of visits for consumers aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration.

### **EXAMPLE**

*Eligible Population or Denominator:* Calculate the denominator as follows, with the measurement period being the measurement year (MY):

1. Number of consumers aged 18 or older who were seen at the clinic during the MY: 1,000
2. Number of visits during the MY by those 1,000 consumers: 6,000
3. Number of visits where the consumer was in an urgent or emergent medical situation where time was of the essence and to delay treatment would jeopardize the consumer's health status: 500
4. Of the 5,500 nonexcluded visits, 3,000 are by Medicaid beneficiaries, 1,000 are by consumers who are beneficiaries of both Medicare and Medicaid, and 1,500 are by consumers who are neither.

Appendix DOC.A: Documentation of Current Medications in the Medical Record

Calculate as follows:

| Steps in calculation  | Medicaid                     | Medicare & Medicaid          | Neither                      | Total                        |
|---|------------------------------|------------------------------|------------------------------|------------------------------|
| Number of visits by age and encounter-eligible consumers during the MY                | 3,200                        | 1,200                        | 1,600                        | 6,000                        |
| From those, exclude visits where there were medical reasons for not screening (G8430) | 200                          | 200                          | 100                          | 500                          |
| <b>Denominator</b>  | <b>3,200-200 =<br/>3,000</b> | <b>1,200-200 =<br/>1,000</b> | <b>1,600-100 =<br/>1,500</b> | <b>6,000-500 =<br/>5,500</b> |

**Numerator:** Calculate the numerator as follows, with the measurement period being the MY:

| Steps in calculation  | Medicaid     | Medicare & Medicaid | Neither      | Total        |
|---|--------------|---------------------|--------------|--------------|
| Denominator   | 3,000        | 1,000               | 1,500        | 5,500        |
| Documentation of current medications in medical record (G8427)    | 2,500        | 800                 | 1,000        | 4,300        |
| No documentation of current medications in medical record (G8428) | 500          | 200                 | 500          | 1,200        |
| <b>Numerator</b>  | <b>2,500</b> | <b>800</b>          | <b>1,000</b> | <b>4,300</b> |

**Quality Measure, percentage of visits for consumers aged 18 years and older for which the eligible professional attests to documenting a list of current medications on the date of the encounter:**

**Medicaid:**  $2,500/3,000 = .833 = .83$  or **83%**

**Medicare & Medicaid:**  $800/1,000 = .800 = .80$  or **80%**

**Neither:**  $1,000/1,500 = .666 = .67$  or **67%**

Appendix DOC.A: Documentation of Current Medications in the Medical Record

**Total:**  $4,300/5,500 = .782 = .78$  or **78%**

Measure interpretation: For the Medicaid consumers aged 18 years and older in the eligible population, 83% of their visits had documentation that a list of current medications was available on the date of the encounter.

## Appendix DOC.B: Documentation of Current Medications in the Medical Record

Codes that may apply to this measure are provided below.

| Category  | Codes   |
|---|---|
| Eligible population step 1, encounter codes   | 90791, 90792, 90832, 90834, 90837, 90839, 90957, 90958, 90959, 90960, 90962, 90965, 90966, 92002, 92004, 92012, 92014, 92507, 92508, 92526, 92541, 92542, 92543, 92544, 92545, 92547, 92548, 92557, 92567, 92568, 92570, 92585, 92588, 92626, 96116, 96150, 96151, 96152, 97001, 97002, 97003, 97004, 97532, 97802, 97803, 97804, 98960, 98961, 98962, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99221, 99222, 99223, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99495, 99496, G0101, G0108, G0270, G0402, G0438, G0439 |
| Current Medications not Documented, Patient not Eligible  | G8430   |
| Eligible professional attests to documenting in the medical record they obtained, updated, or reviewed the consumer's current medications | G8427   |
| Current list of medications not documented as obtained, updated, or reviewed by the eligible professional, reason not given               | G8428   |



## Appendix BMI-SF.A: Preventive Care & Screening: Body Mass Index (BMI) Screening & Follow-Up

Percentage of consumers aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter.

Normal Parameters: Age 65 years and older BMI  $\geq 23$  and  $< 30$  kg/m<sup>2</sup>

Age 18 - 64 years BMI  $\geq 18.5$  and  $< 25$  kg/m<sup>2</sup>

### EXAMPLE

***Eligible Population or Denominator:*** Calculate the denominator as follows, with the measurement period being the measurement year (MY):

1. Consumers aged 18 years or older who were seen at the clinic with one of the denominator-eligible encounter codes during the MY: 200
2. Exclusions:
  - a. BMI Not Documented, Consumer Not Eligible: 15
  - b. BMI Documented Outside of Normal Limits and Follow-Up Plan Not Documented in MY, Consumer Not Eligible: 4
  - c. No quality-data codes reported: 1  
200-20=180
3. Of the 180 non-excluded consumers, 100 are Medicaid beneficiaries, 20 are Medicaid & Medicare eligible, and 60 are neither.

Calculate as follows:

| Steps in calculation  | Medicaid | Medicaid & Medicare | Neither | Total |
|---|----------|---------------------|---------|-------|
| Consumers aged 18 years or older seen during MY with denominator-eligible encounter codes | 109      | 28                  | 63      | 200   |

Appendix BMI-SF.A: Preventive Care & Screening: Adult Body Mass Index (BMI) Screening & Follow-Up

| <b>Steps in calculation</b>   | <b>Medicaid</b> | <b>Medicaid &amp; Medicare</b> | <b>Neither</b> | <b>Total</b> |
|---|-----------------|--------------------------------|----------------|--------------|
| BMI Not Documented, Consumer Not Eligible (G8422)   | 6               | 7                              | 2              | 15           |
| BMI Documented Out of Normal Limits, Follow-Up Plan Not Documented in MY, Consumer Not Eligible (G8938) | 2               | 1                              | 1              | 4            |
| No quality-data numerator codes reported  | 1               | 0                              | 0              | 1            |
| <b>Denominator</b>  | <b>100</b>      | <b>20</b>                      | <b>60</b>      | <b>180</b>   |

***Numerator:*** Calculate as follows, with the measurement period for the numerator being the measurement year and six months prior:

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicaid &amp; Medicare</b> | <b>Neither</b> | <b>Total</b> |
|--|-----------------|--------------------------------|----------------|--------------|
| Denominator  | 100             | 20                             | 60             | 180          |
| BMI Not Documented, Reason not Given (G8421)   | 4               | 1                              | 8              | 13           |
| BMI Documented Outside of Normal Parameters, Follow-Up Plan not Documented, Reason not Given (G8419) | 7               | 1                              | 10             | 18           |
| <b>Numerator</b>   | <b>89</b>       | <b>18</b>                      | <b>42</b>      | <b>149</b>   |

***Quality Measure, Percentage of consumers aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with***

*a BMI of normal parameters, and with a follow-up plan documented during the encounter or during the previous six months of the current encounter:*

**Medicaid:**  $89/100 = .890 = .89$  or **89%**

**Medicaid & Medicare:**  $18/20 = .900 = .90$  or **90%**

**Neither:**  $42/60 = .700 = .70$  or **70%**

**Total:**  $149/180 = .827 = .83$  or **83%**

Metric interpretation: 89% of the Medicaid consumers in the eligible population who were 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI of normal parameters, had a follow-up plan that was documented during the encounter or during the previous six months of the current encounter; whereas, only 70% of consumers without Medicaid or Medicare (referred to as “Neither”) had a follow-up plan documented under the same criteria.

**Appendix BMI-SF.B. Codes Relevant to Preventive Care & Screening: Adult  
Body Mass Index (BMI) Screening and Follow-Up**

Codes that may apply to this measure are provided below.

| <b>Category</b>   | <b>Codes</b>  |
|---|---|
| Eligible population step 2, encounter codes   | 90791, 90792, 90832, 90834, 90837, 90839, 96150, 96151, 96152, 97001, 97003, 97802, 97803, 98960, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, D7140, D7210, G0101, G0108, G0270, G0271, G0402, G0438, G0439, G0447 |
| BMI not documented with documentation the consumer is not eligible for BMI calculation  | G8422   |
| BMI is documented as being outside of normal limits, follow-up plan is not documented, documentation shows the consumer is not eligible | G8938   |
| BMI is documented within normal parameters and no follow up plan is required  | G8420   |
| BMI is documented above normal parameters and a follow-up plan is documented  | G8417   |
| BMI is documented below normal parameters and a follow-up plan is documented  | G8418   |
| BMI not documented and no reason is given   | G8421   |
| BMI documented outside normal parameters, no follow-up plan documented, no reason given   | G8419   |

**Appendix CBP-BH. Controlling High Blood Pressure****Table CBP-A: Prescriptions to Identify Consumers with Diabetes**

| Description                  | Prescription  |
|------------------------------|---|
| Alpha-glucosidase inhibitors | Acarbose<br>Miglitol  |
| Amylin analogs               | Pramlintide   |
| Antidiabetic combinations    | Alogliptin-metformin<br>Alogliptin-pioglitazone<br>Canagliflozin-metformin<br>Empagliflozin-linagliptin<br>Empagliflozin/metformin<br>Glimepiride-pioglitazone<br>Glimepiride-rosiglitazone<br>Glipizide-metformin<br>Glyburide-metformin<br>Linagliptin-metformin<br>Metformin-pioglitazone<br>Metformin-repaglinide<br>Metformin-rosiglitazone<br>Metformin-saxagliptin<br>Metformin-sitagliptin<br>Sitagliptin-simvastatin |
| Insulin                      | Insulin aspart<br>Insulin aspart-insulin aspart protamine<br>Insulin detemir<br>Insulin glargine<br>Insulin glulisine<br>Insulin human inhaled<br>Insulin isophane human<br>Insulin isophane-insulin regular<br>Insulin lispro<br>Insulin lispro-insulin lispro protamine<br>Insulin regular human  |

Appendix CBP-BH: Controlling High Blood Pressure

Please see NCQA Notice of Copyright and Disclaimers in front matter to Volume 1 of this manual.

| Description                                      | Prescription  |
|--|---|
| Meglitinides                                     | Nateglinide<br>Repaglinide  |
| Glucagon-like peptide-1 (GLP1) agonists          | Dulaglutide<br>Exenatide<br>Liraglutide<br>Albiglutide                            |
| Sodium glucose cotransporter 2 (SGLT2) inhibitor | Canagliflozin<br>Dapagliflozin<br>Empagliflozin                                   |
| Sulfonylureas                                    | Chlorpropamide<br>Glimepiride<br>Glipizide<br>Glyburide<br>Tolazamide Tolbutamide |
| Thiazolidinediones                               | Pioglitazone<br>Rosiglitazone   |
| Dipeptidyl peptidase-4 (DDP-4) inhibitors        | Alogliptin<br>Linagliptin<br>Saxagliptin<br>Sitagliptin                           |

**Note:** Glucophage/metformin as a solo agent is not included because it is used to treat conditions other than diabetes; consumers with diabetes on these medications are identified through diagnosis codes only.

**Note:** Table CBP-A corresponds to NDC Code Table CDC-A posted to [HEDIS NDC page](#)

## Appendix TSC.A: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention

Percentage of consumers aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation intervention if identified as a tobacco user

### EXAMPLE

***Eligible Population or Denominator:*** Calculate the denominator as follows, with the measurement period (MP) being the measurement year (MY):

1. Consumers seen at the clinic who were aged 18 years or older on the date of first denominator eligible visit during the MY: 200
2. Of the 200 consumers, 100 are Medicaid beneficiaries, 50 are beneficiaries of both Medicare and Medicaid, and 50 are neither.
3. Consumers without quality-data code needed for numerator: 13

Calculate as follows:

| <b>Steps in calculation</b>                         | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|---|-----------------|--------------------------------|----------------|--------------|
| Age and encounter-eligible consumers seen during MY | 100             | 50                             | 50             | 200          |
| No quality-data numerator codes reported            | 5               | 5                              | 3              | 13           |
| <b>Denominator</b>                                  | <b>95</b>       | <b>45</b>                      | <b>47</b>      | <b>187</b>   |

**Numerator:** Calculate the numerator as follows, with the MP being the measurement year and the year before:

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b>  | <b>Total</b>      |
|--|-----------------|--------------------------------|-----------------|-------------------|
| Denominator  | 95              | 45                             | 47              | 187               |
| Remove consumers with a documented medical reason for not screening for tobacco use during the MY or the year prior (4004F with 1P)  | 15              | 30                             | 2               | 47                |
| Exclude consumers not screened for tobacco use during the MP, reason not otherwise specified (4004F with 8P)   | 10              | 7                              | 8               | 25                |
| Exclude consumers who were screened for tobacco use and who were identified as tobacco users, but who did not receive a tobacco cessation intervention during the MP, reason not otherwise specified (4004F with 8P) | 16              | 5                              | 10              | 37                |
| <b>Numerator</b>   | <b>95-41=54</b> | <b>45-42=3</b>                 | <b>47-20=27</b> | <b>187-109=78</b> |

**Quality Measure, percentage of consumers aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation intervention if identified as a tobacco user :**

**Medicaid:**  $54/95 = .57$  or 57%



**Medicare & Medicaid:**  $3/45 = .07$  or **7%**

**Neither:**  $27/47 = .57$  or **57%**

**Total:**  $78/187 = .530 = .42$  or **42%**

Measure interpretation: For the Medicaid consumers in the eligible population, 57% aged 18 years and older were screened for tobacco use one or more times within 24 months AND received cessation intervention if identified as a tobacco user.

## Appendix TSC.B: Preventive Care & Screening: Tobacco Use: Screening & Cessation Intervention

Codes that may apply to this measure are provided below.

| Category  | Codes   |
|---|---|
| Eligible population step 3, encounter codes   | 90791, 90792, 90832, 90834, 90837, 90845, 92002, 92004, 92012, 92014, 92521, 92522, 92523, 92524, 92540, 92557, 92625, 96150, 96151, 96152, 97003, 97004, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99406, 99407, G0438, G0439 |
| Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reasons)                           | CPT II 4004F with 1P  |
| Consumer screened for tobacco use AND received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user | CPT II 4004F  |
| Consumer screened for tobacco use and identified as a non-user of tobacco   | CPT II 1036F  |
| Tobacco screening OR tobacco cessation intervention not performed, reason not otherwise specified   | CPT II 4004F with 8P  |

## **Appendix ASC.A: Preventive Care & Screening: Unhealthy Alcohol Use: Screening & Brief Counseling**

Percentage of consumers aged 18 years and older who were screened at least once within the last 24 months for unhealthy alcohol use using a systematic screening method AND who received brief counseling if identified as an unhealthy alcohol user

### **EXAMPLE**

***Eligible Population or Denominator:*** Calculate the denominator as follows, with the measurement period being the measurement year (MY):

1. Consumers seen at the clinic who were aged 18 or older on the date of first denominator-eligible visit during the MY: 200
2. Of the 200 consumers, 100 are Medicaid beneficiaries, 50 are beneficiaries of both Medicare and Medicaid, and 50 are neither.
3. Consumers seen at least twice for any denominator-eligible visit or at least once for preventive care visit during the MY: 140
4. Consumers without quality-data code needed for numerator: 13

Calculate as follows:

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b>      |
|--|-----------------|--------------------------------|----------------|-------------------|
| Age-eligible consumers seen during MY  | 100             | 50                             | 50             | 200               |
| From those, consumers who were seen at least twice for any denominator-eligible visit or at least once for preventive care visit during the MY | 70              | 40                             | 30             | 140               |
| No quality-data numerator codes reported   | 5               | 5                              | 3              | 13                |
| <b>Denominator</b>   | <b>70-5=65</b>  | <b>40-5=35</b>                 | <b>30-3=27</b> | <b>140-13=127</b> |

**Numerator:** Calculate the numerator as follows, with the measurement period (MP) being the measurement year and the year before:

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|--|-----------------|--------------------------------|----------------|--------------|
| Denominator  | 65              | 35                             | 27             | 127          |
| From those, remove consumers with a documented medical reason(s) for not screening for unhealthy alcohol use in the MY or the year prior (G9623) | 5               | 5                              | 3              | 13           |

| <b>Steps in calculation</b>   | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b>     |
|---|-----------------|--------------------------------|----------------|------------------|
| From those, exclude consumers not screened during the MP using a systematic screening method (G9624)  | 10              | 10                             | 10             | 30               |
| From those, exclude consumers identified as unhealthy alcohol users when screened for unhealthy alcohol use at least once during MP, who did not receive brief counseling during MP (G9624) | 25              | 10                             | 10             | 45               |
| <b>Numerator</b>  | <b>65-40=25</b> | <b>35-25=10</b>                | <b>27-23=4</b> | <b>127-88=39</b> |

*Quality Measure, percentage of consumers aged 18 years and older who were screened at least once within the last 24 months for unhealthy alcohol use using a systematic screening method AND who received brief counseling if identified as an unhealthy alcohol user:*

**Medicaid:**  $25/65 = .38$  or **38%**

**Medicare & Medicaid:**  $10/35 = .29$  or **29%**

**Neither:**  $4/27 = .15$  or **15%**

**Total:**  $39/127 = .31$  or **31%**

Measure interpretation: Of the Medicaid consumers within the eligible population aged 18 years and older, 38% were screened at least once within the last 24 months for unhealthy alcohol use using a systematic screening method AND received brief counseling if identified as an unhealthy alcohol user; whereas, for those consumers without Medicare or Medicaid coverage, referred to as “Neither,” only 15% received such screening and counseling.

## Appendix ASC.B: Preventive Care & Screening: Unhealthy Alcohol Use: Screening & Brief Counseling

Codes that may apply to this measure are provided below.

| Category   | Codes   |
|--|---|
| Eligible population step 3, non-preventive care encounter codes  | 90791, 90792, 90832, 90834, 90837, 90845, 96150, 96151, 96152, 97003, 97004, 97802, 97803, 97804, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, G0270, G0271 |
| Eligible population step 3, preventive care encounter codes  | G0438, G0439  |
| Documentation of medical reason(s) for not screening for unhealthy alcohol use (e.g., limited life expectancy, other medical reasons)                      | G9623   |
| Consumer identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling | G9621   |
| Consumer not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method                           | G9622   |
| Consumer not screened for unhealthy alcohol screening using a systematic screening method OR consumer did not receive brief counseling, reason not given   | G9624   |

## **Appendix SRA-BH-C: eCQM Flow for Reporting the Suicide Risk Assessment (SRA-BH-C) Measure**

**Refer to the specific section of the SRA-BH-C specifications to identify the Quality Data Model (QDM) data elements and associated value sets for use in reporting this measure.**

- 1. Start Initial Consumer Population**
- 2. Check Consumer Characteristic Birthdate:**
  - a. If QDM data element, BIRTH DATE, is greater than or equal to 6 years of age AND less than 17 years of age before the start of the measurement period equals No, do not include in Initial Consumer Population. Stop Processing.
  - b. If QDM data element, BIRTH DATE, is greater than or equal to 6 years of age AND less than 17 years of age before the start of the measurement period, equals Yes, continue processing and proceed to check Encounter Performed.
- 3. Check Encounter Performed:** Total number of encounters must be greater than or equal to 2:
  - a. If QDM data element, OFFICE VISIT, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check for another Encounter Performed until total number of encounters are greater than or equal to 2.
  - b. If QDM data element, OFFICE VISIT, during the measurement period equals No, proceed to check next Encounter Performed.
  - c. If QDM data element, OUTPATIENT CONSULTATION, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check for another Encounter Performed until total number of encounters are greater than or equal to 2.
  - d. If QDM data element, OUTPATIENT CONSULTATION, during the measurement period equals No, proceed to check next Encounter Performed.
  - e. If QDM data element, CONSUMER PROVIDER INTERACTION, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check for another Encounter Performed until total number of encounters are greater than or equal to 2.
  - f. If QDM data element, CONSUMER PROVIDER INTERACTION, during the measurement period equals No, proceed to check next Encounter Performed.
  - g. If QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION, during the measurement period equals Yes, include in the Initial Consumer Population and proceed

to check for another Encounter Performed until total number of encounters are greater than or equal to 2.

- h. If QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION, during the measurement period equals No, proceed to check next Encounter Performed.
  - i. If QDM data element, PSYCH VISIT – FAMILY PSYCHOTHERAPY, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check for another Encounter Performed until total number of encounters are greater than or equal to 2.
  - j. If QDM data element, PSYCH VISIT – FAMILY PSYCHOTHERAPY, during the measurement period equals No, proceed to check next Encounter Performed.
  - k. If QDM data element, PSYCHOANALYSIS, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check for another Encounter Performed until total number of encounters are greater than or equal to 2.
  - l. If QDM data element, PSYCHOANALYSIS, during the measurement period equals No, proceed to check next Encounter Performed.
  - m. If QDM data element, GROUP PSYCHOTHERAPY, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check for another Encounter Performed until total number of encounters are greater than or equal to 2.
  - n. If QDM data element, GROUP PSYCHOTHERAPY, during the measurement period equals No, do not include in the Initial Consumer Population and proceed to check next Encounter Performed.
  - o. If QDM data element, PSYCH VISIT - PSYCHOTHERAPY, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to check Diagnosis Active if total number of encounters are greater than or equal to 2.
  - p. If QDM data element, PSYCH VISIT - PSYCHOTHERAPY, during the measurement period equals No, do not include in the Initial Consumer Population. Stop Processing.
4. **Check Diagnosis Active:**
- a. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION, during measurement period equals Yes include in Initial Consumer Population and continue on to the Denominator.
  - b. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION, during measurement period equals No proceed to check next Diagnosis Active.



- c. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER -ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – FAMILY PSYCHOTHERAPY, during measurement period equals Yes include in Initial Consumer Population and continue on to the Denominator.
- d. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – FAMILY PSYCHOTHERAPY, during measurement period equals No, proceed to check next Diagnosis Active.
- e. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, during measurement period equals Yes, include in Initial Consumer Population and continue on to the Denominator.
- f. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, during measurement period equals No, proceed to check next Diagnosis Active.
- g. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, GROUP PSYCHOTHERAPY, during measurement period equals Yes, include in Initial Consumer Population and continue on to the Denominator.
- h. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, GROUP PSYCHOTHERAPY, during measurement period equals No, proceed to check next Diagnosis Active.
- i. If Occurrence A of QDM data element, MAJOR DEPRESSIVE - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION, during measurement period equals Yes, include in Initial Consumer Population and continue on to the Denominator.
- j. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION, during measurement period equals No, proceed to check next Diagnosis Active.
- k. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter

Performed QDM data element, OFFICE VISIT, during measurement period equals Yes, include in Initial Consumer Population and continue on to the Denominator.

- l. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, during measurement period equals No, proceed to check next Diagnosis Active.
- m. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS, during measurement period equals Yes, include in Initial Consumer Population and continue on to the Denominator.
- n. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS, during measurement period equals No, proceed to check next Diagnosis active.
- o. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE, starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – PSYCHOTHERAPY, during measurement period equals Yes, include in Initial Consumer Population and continue on to the Denominator.
- p. If Occurrence A of QDM data element, MAJOR DEPRESSIVE DISORDER - ACTIVE starts before or during but does not end before the start of Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – PSYCHOTHERAPY, during measurement period equals No, do not include in the Initial Consumer Population. Stop Processing.

**5. Start Denominator**

- a. Denominator equals the Initial Consumer Population. Denominator is represented by the letter B in the sample calculation listed at the end of this document. Letter B equals 10 consumers in the sample calculation.

**6. Start Numerator**

**7. Check Intervention Performed:**

- a. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- b. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT –

DIAGNOSTIC EVALUATION equals No, proceed to check next Intervention Performed.

- c. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – FAMILY PSYCHOTHERAPY equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- d. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – FAMILY PSYCHOTHERAPY equals No, proceed to check next Intervention Performed.
- e. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- f. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION equals No, proceed to check next Intervention Performed.
- g. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, GROUP PSYCHOTHERAPY equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- h. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, GROUP PSYCHOTHERAPY equals No, proceed to check next Intervention Performed.
- i. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- j. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION equals No, proceed to check next Intervention Performed.
- k. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.


- l. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT equals No, proceed to check next Intervention Performed.
- m. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- n. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS equals No, proceed to check next Intervention Performed.
- o. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT - PSYCHOTHERAPY equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 5 consumers in the sample calculation.
- p. If Occurrence A of QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT - PSYCHOTHERAPY equals No, include in the No/Missing Numerator Data Submitted count and stop processing.

### **Sample Calculation**

Performance Rate = Numerator (a=5 consumers) ÷ Denominator (b=10 consumers) – Denominator Exclusions (N/A) – Denominator Exceptions (N/A) = 50.00%

Appendix SRA-BH-C: eCQM Flow for Reporting the Suicide Risk Assessment (SRA-BH-C) Measure

2014 eCQM Flow  
 Measure Identifier: CMS177v3  
 NQF 1365: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment



\*Please refer to the specific section of the eCQM to identify the QDM data elements and associated value sets for use in reporting this eCQM.  
 ‡ Appropriate encounters include; Office Visit, Outpatient Consultation, Patient Provider Interaction, Psych Visit – Diagnostic Evaluation, Psych Visit – Family Psychotherapy, Psychoanalysis, Group Psychotherapy, and Psych Visit – Psychotherapy.  
 ‡‡ Appropriate encounters include; Psych Visit – Diagnostic Evaluation, Psych Visit – Family Psychotherapy, Face-to-Face Interaction, Group Psychotherapy, Outpatient Consultation, Office Visit, Psychoanalysis, and Psych Visit – Psychotherapy.

**SAMPLE CALCULATION:**

**Performance Rate =**  

$$\frac{\text{Numerator (a=5 patients)}}{\text{Denominator (b=10 patients) - Denominator Exclusions (N/A) - Denominator Exceptions (N/A)}} = 50.00\%$$

## **Appendix SRA-A.A: eCQM Flow for Reporting the Suicide Risk Assessment (SRA-A) Measure**

**Refer to the specific section of the SRA-A specifications to identify the Quality Data Model (QDM) data elements and associated value sets for use in reporting this measure.**

### **1. Start Initial Consumer Population**

#### **2. Check Consumer Characteristic Birthdate:**

a. If the QDM data element, BIRTH DATE, is greater than or equal to 17 years of age starts before the start of the measurement period equals No, do not include in Initial Consumer Population. Stop Processing.

b. If the QDM data element, BIRTH DATE, is greater than or equal to 17 years of age starts before the start of the measurement period, equals Yes continue processing and proceed to check Diagnosis Active.

#### **3. Check Diagnosis Active:**

a. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element PSYCH VISIT – DIAGNOSTIC EVALUATION, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.

b. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element PSYCH VISIT – DIAGNOSTIC EVALUATION, during the measurement period equals No, proceed to check next Diagnosis Active.

c. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT - PSYCHOTHERAPY, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.

d. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element PSYCH VISIT - PSYCHOTHERAPY, during the measurement period equals No, proceed to check next Diagnosis Active.

e. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element, EMERGENCY DEPARTMENT VISIT, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.

- f. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element EMERGENCY DEPARTMENT VISIT, during the measurement period equals No, proceed to check next Diagnosis Active.
- g. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.
- h. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element OFFICE VISIT, during the measurement period equals No, proceed to check next Diagnosis Active.
- i. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.
- j. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element OUTPATIENT CONSULTATION, during the measurement period equals No, proceed to check next Diagnosis Active.
- k. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.
- l. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element PSYCHOANALYSIS, during the measurement period equals No, proceed to check next Diagnosis Active.
- m. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, during the measurement period equals Yes, include in the Initial Consumer Population and proceed to Denominator.
- n. If the QDM data element, MAJOR DEPRESSIVE DISORDER ACTIVE, starts during Occurrence A of Encounter Performed QDM data element FACE-TO-FACE INTERACTION, during the measurement period equals No, do not include in Initial Consumer Population. Stop Processing.

#### **4. Start Denominator**

a. Denominator equals the Initial Consumer Population. Denominator is represented by the letter B in the sample calculation listed at the end of this document. Letter B equals 10 consumers in the sample calculation.

**5. Start Numerator**

**6. Check Intervention Performed:**

a. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.

b. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – DIAGNOSTIC EVALUATION equals No, proceed to check next Intervention Performed.

c. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – PSYCHOTHERAPY equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.

d. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCH VISIT – PSYCHOTHERAPY equals No, proceed to check next Intervention Performed.

e. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, EMERGENCY DEPARTMENT VISIT equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.

f. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, EMERGENCY DEPARTMENT VISIT equals No, proceed to check next Intervention Performed.

g. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.

h. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT equals No, proceed to check next Intervention Performed.




- i. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION, equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.
- j. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, OUTPATIENT CONSULTATION equals No, proceed to check next Intervention Performed.
- k. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS, equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.
- l. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, PSYCHOANALYSIS equals No, proceed to check next Intervention Performed.
- m. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, equals Yes, include in the Numerator count. The Numerator is represented by the letter A in the sample calculation listed at the end of this document. Letter A equals 7 consumers in the sample calculation.
- n. If QDM data element SUICIDE RISK ASSESSMENT during Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION equals No, include in No/Missing Numerator Data Submitted. Stop Processing.

### **Sample Calculation**

Performance Rate = Numerator (a=7 consumers) ÷ Denominator (b=10 consumers) – Denominator Exclusions (N/A) – Denominator Exceptions (N/A) = 70.00%

Appendix SRA-A.A: eCQM Flow for Reporting the Suicide Risk Assessment (SRA-A) Measure

2014 eCQM Flow  
 Measure Identifier: CMS161v3  
 NQF 0104: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment



\*Please refer to the specific section of the eCQM to identify the QDM data elements and associated value sets for use in reporting this eCQM.  
 ‡ The appropriate encounters include: Psych Visit - Diagnostic Evaluation, Psych Visit - Psychotherapy, Emergency Department Visit, Office Visit, Outpatient Consultation, Psychoanalysis, and Face-to-Face Interaction. .

**SAMPLE CALCULATION:**

Performance Rate = 
$$\frac{\text{Numerator (a = 7 patients)}}{\text{Denominator (b = 10 patients) - Denominator Exclusions (N/A) - Denominator Exceptions (N/A)}} = 70.00\%$$

## Appendix SRA-A.B: Major Depressive Disorder (MDD): Suicide Risk Assessment

Codes that may apply to this measure are provided below.

| Category  | Codes  |
|---|--|
| Eligible population step 2, diagnosis and encounter codes | <p>International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes for MDD: F32.0, F32.1, F32.2, F32.3, F32.9, F33.0, F33.1, F33.2, F33.3, and F33.9</p> <p>Current Procedural Terminology [CPT<sup>®</sup>] codes for the encounter: 90791, 90792, 90832, 90834, 90837, 90845, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, and 99245</p> |

## Appendix SRA-A.C: Major Depressive Disorder (MDD): Suicide Risk Assessment

Percentage of consumers aged 18 years and older with a diagnosis of Major Depressive Disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified

### EXAMPLE

**Eligible Population or Denominator:** Calculate the denominator as follows, with the measurement period (MP) being the measurement year (MY):

1. Consumers seen at the clinic during the MY with a denominator-eligible encounter and new diagnosis or recurrent episode of MDD: 200
2. Of the 200 consumers, 100 are Medicaid beneficiaries, 50 are beneficiaries of both Medicare and Medicaid, and 50 are neither.
3. Of the 200 consumers, the number that were 18 or older at the time of the diagnosis or episode: 160
4. Among those 18 or older, the total number of such new diagnoses or recurrent episodes identified during the MY: 150

Calculate as follows:

| Steps in calculation   | Medicaid | Medicaid & Medicare | Neither | Total |
|--|----------|---------------------|---------|-------|
| The number of consumers with a new diagnosis or recurrent episode of MDD during the MY           | 100      | 50                  | 50      | 200   |
| Out of those, the number aged 18 and older at the time of the new diagnosis or recurrent episode | 80       | 35                  | 45      | 160   |

| <b>Steps in calculation</b>   | <b>Medicaid</b> | <b>Medicaid &amp; Medicare</b> | <b>Neither</b> | <b>Total</b> |
|---|-----------------|--------------------------------|----------------|--------------|
| Among those, the number of new diagnoses or recurrent episodes identified during the MY | 85              | 30                             | 35             | 150          |
| <b>Denominator</b>  | <b>85</b>       | <b>30</b>                      | <b>35</b>      | <b>150</b>   |

**Numerator:** Calculate the numerator as follows, with the MP being the MY:

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|--|-----------------|--------------------------------|----------------|--------------|
| Denominator  | 85              | 30                             | 35             | 150          |
| From the denominator, the number of visits in which the diagnosis or recurrence was identified, where a suicide risk assessment was conducted during the visit | 80              | 25                             | 20             | 125          |
| <b>Numerator</b>   | <b>80</b>       | <b>25</b>                      | <b>20</b>      | <b>125</b>   |

**Quality Measure, percentage of consumers aged 18 years and older with a diagnosis of Major Depressive Disorder (MDD) and with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified:**

**Medicaid:**  $80/85 = .941 = .94$  or **94%**

**Medicare & Medicaid:**  $25/30 = .830 = .83$  or **83%**

**Neither:**  $20/35 = .570 = .57$  or **57%**

**Total:**  $125/150 = .830 = .83$  or **83**

Measure interpretation: For the Medicaid consumers aged 18 years and older with a diagnosis of Major Depressive Disorder (MDD), 94% had a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified. In contrast, for those consumers without Medicare or Medicaid (defined as “Neither”), only 57% had a suicide risk assessment completed during the same visit.

## Appendix CDF-BH.A: Screening for Clinical Depression and Follow-Up Plan

Percentage of consumers aged 12 years and older screened for clinical depression on the date of the encounter using an age-appropriate standardized depression screening tool, and if positive, a follow-up plan is documented on the date of the positive screen

### EXAMPLE

**Eligible Population or Denominator:** Calculate the denominator as follows, with the measurement period (MP) being the measurement year (MY):

1. Consumers seen at the clinic who were aged 12 years or older on the date of first denominator eligible visit during the MY: 400
2. Of the 400 consumers, 250 are Medicaid beneficiaries, 100 are beneficiaries of both Medicare and Medicaid, and 50 are neither.
3. Consumers excluded due to active diagnosis of Depression or Bipolar Disorder: 20; due to refusal to participate: 15; due to emergency: 20; due to functional capacity or motivation: 15. Total: 70.

Calculate as follows:

| Steps in calculation   | Medicaid   | Medicare & Medicaid | Neither   | Total      |
|--|------------|---------------------|-----------|------------|
| Age and outpatient encounter-eligible consumers seen during MY | 250        | 100                 | 50        | 400        |
| Exclusions   | 45         | 15                  | 10        | 70         |
| <b>Denominator</b>   | <b>205</b> | <b>85</b>           | <b>40</b> | <b>330</b> |

**Numerator:** Calculate the numerator as follows, with the MP being the measurement year:

- Positive screen for clinical depression using a standardized tool and a follow-up plan documented (G8431).

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|--|-----------------|--------------------------------|----------------|--------------|
| Denominator  | 205             | 85                             | 40             | 330          |
| Consumers screened for clinical depression with positive screen                    | 100             | 55                             | 5              | 160          |
| Consumers with positive screen who had a follow-up plan documented on the same day | 90              | 30                             | 3              | 123          |
| <b>Numerator</b>   | <b>90</b>       | <b>30</b>                      | <b>3</b>       | <b>123</b>   |

*Quality Measure, percentage of consumers aged 12 years and older screened for clinical depression on the date of the encounter using an age-appropriate standardized depression screening tool, and if positive, a follow-up plan is documented on the date of the positive screen, by payer status:*

**Medicaid:**  $90/205 = .44$  or **44%**

**Medicare & Medicaid:**  $30/85 = .35$  or **35%**

**Neither:**  $3/40 = .08$  or **8%**

**Total:**  $123/330 = .37$  or **37%**

Metrics interpretation: For the Medicaid eligible population, 44% of consumers were screened and had a positive result for clinical depression and were also documented with a follow-up plan on the same date as the screening; whereas, 35% with both Medicare and Medicaid and 8% without Medicare or Medicaid (referred to as “Neither”) were both screened and positive for clinical depression and were documented to have a follow-up plan put in place on the same day.

See below for similar calculation stratified by age:



***Denominator:***

| <b>Steps in calculation</b>                                    | <b>Aged 12-17 years</b> | <b>Aged 18-64 years</b> | <b>Aged 65 years and older</b> | <b>Total</b> |
|--|-------------------------|-------------------------|--------------------------------|--------------|
| Age and outpatient encounter-eligible consumers seen during MY | 100                     | 225                     | 75                             | 400          |
| Exclusions   | 20                      | 40                      | 10                             | 70           |
| <b>Denominator</b>   | <b>80</b>               | <b>185</b>              | <b>65</b>                      | <b>330</b>   |

***Numerator:***

| <b>Steps in calculation</b>  | <b>Aged 12-17 years</b> | <b>Aged 18-64 years</b> | <b>Aged 65 years and older</b> | <b>Total</b> |
|--|-------------------------|-------------------------|--------------------------------|--------------|
| Denominator  | 80                      | 185                     | 65                             | <b>330</b>   |
| Consumers screened for clinical depression with positive screen                    | 65                      | 170                     | 35                             | 270          |
| Consumers with positive screen who had a follow-up plan documented on the same day | 40                      | 63                      | 20                             | 123          |
| <b>Numerator</b>   | <b>40</b>               | <b>63</b>               | <b>20</b>                      | <b>123</b>   |

***Quality Metric, percentage of consumers aged 12 years and older screened for clinical depression on the date of the encounter using an age-appropriate standardized depression screening tool, and if positive, a follow-up plan is documented on the date of the positive screen, by age category:***

**Aged 12-17:**  $40/80 = .50$  or **50%**

**Aged 18-64:**  $63/185 = .34$  or **34%**

**Aged 65 and older:**  $20/65 = .31$  or **31%**

**Total:**  $123/330 = .37$  or **37%**

Metrics interpretation: For those consumers in the eligible population aged 65 years and older, 31% who were screened and had a positive result for clinical depression were also documented with a follow-up plan on the same date as the screening; whereas, 34% of consumers aged 18 to 64 years and 50% of those aged 12 to 17 years had a positive clinical depression screen and follow-up plan was needed.

**Appendix CDF-BH.B: Screening for Clinical Depression and Follow-Up Plan****Table CDF-A. Codes to Identify Outpatient Visits**

| <b>CPT</b>  | <b>HCPCS</b>                      |
|---|-----------------------------------|
| 90791, 90792, 90832, 90834, 90837, 90839, 92625, 96116, 96118, 96150, 96151, 97003, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215 | G0101, G0402, G0438, G0439, G0444 |

**Table CDF-B. Codes to Document Clinical Depression Screen**

| <b>Code</b> | <b>Description</b>   |
|-------------|--|
| G8431       | Positive screen for clinical depression using a standardized tool and a follow-up plan documented.                               |
| G8510       | Negative screen for clinical depression using standardized tool, patient not eligible/appropriate for follow-up plan documented. |

**Table CDF-C. Codes to Identify Exclusions**

| <b>Code</b>      | <b>Description</b>  |
|------------------|---|
| G8433            | Screening for clinical depression not documented, patient not eligible/appropriate.   |
| G8940            | Screening for clinical depression documented, follow-up plan not documented, patient not eligible/appropriate.  |
| Depression       | F320, F321, F322, F323, F324, F325, F328, F329, F330, F331, F332, F333, F3340, F3341, F3342, F338, F339, F341   |
| Bipolar Disorder | F310, F3110, F3111, F3112, F3113, F312, F3130, F3131, F3132, F314, F315, F3160, F3161, F3162, F3163, F3164, F3170, F3171, F3172, F3173, F3174, F3175, F3176, F3177, F3178, F3181, F3189, F319, F3010, F3011, F3012, F3013, F302, F303, F304, F308, F309 |

## Appendix DEP-REM-12. Depression Remission at Twelve Months

Adult consumers age 18 and older with Major Depression or Dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at twelve months defined as a PHQ-9 score less than 5

### EXAMPLE

***Eligible Population or Denominator:***

1. 200 consumers seen at the clinic during the measurement year (MY)
2. Exclusions:
  - a. Died during MY: 10
  - b. Were in hospice during MY: 5
  - c. Became permanent nursing home resident during MY: 0
  - d. Had a diagnosis of bipolar disorder: 30
  - e. Had a diagnosis of personality disorder: 15

**Sum of a. – e. = 10+5+0+30+15=60**

**200-60=140 nonexcluded patients**

3. Of the 140 nonexcluded consumers, 100 were Medicaid beneficiaries and 20 were eligible for both Medicare and Medicaid, and 20 were neither.
4. Compute the rest of the denominator (N=140) as follows:

| <b>Steps in calculation</b>  | <b>Medicaid</b> | <b>Medicare &amp; Medicaid</b> | <b>Neither</b> | <b>Total</b> |
|--|-----------------|--------------------------------|----------------|--------------|
| Nonexcluded consumers seen during the MY   | 100             | 20                             | 20             | 140          |
| From those, consumers whose PHQ-9 score was greater than 9 (at the index date) during the MY | 75              | 20                             | 10             | 105          |

Appendix DEP-REM-12. Depression Remission at Twelve Months

| Steps in calculation  | Medicaid  | Medicare & Medicaid | Neither  | Total     |
|---|-----------|---------------------|----------|-----------|
| From those, consumers with a primary <sup>9</sup> diagnosis of Major Depression or Dysthymia upon scoring greater than 9 on the PHQ-9 at the index date | 55        | 20                  | 5        | 80        |
| From those, consumers aged 18 years and older on the index date when they had a PHQ-9 score greater than 9  | 40        | 15                  | 5        | 60        |
| <b>Denominator</b>  | <b>40</b> | <b>15</b>           | <b>5</b> | <b>60</b> |

**Numerator:** Twelve months after the index date ( $\pm$  30 days), scored less than 5 on the PHQ-9:

| Steps in calculation  | Medicaid        | Medicare & Medicaid | Neither      | Total           |
|---|-----------------|---------------------|--------------|-----------------|
| Eligible consumers after exclusions                                 | 40              | 15                  | 5            | 60              |
| Not administered PHQ-9 during the 60 day window of twelve months    | 4               | 2                   | 1            | 7               |
| Tested during the 60 day window but scored 5 or higher on the PHQ-9 | 7               | 3                   | 1            | 11              |
| <b>Numerator</b>  | <b>40-11=29</b> | <b>15-5=10</b>      | <b>5-2=3</b> | <b>60-18=42</b> |

**Quality Measure, percentage with 12-month depression remission:**

**Medicaid:**  $29/40 = .725 = .73$  or **73%**

**Medicare and Medicaid:**  $10/15 = .666 = .67$  or **67%**

**Neither:**  $3/5 = .60 = .60$  or **60%**

<sup>9</sup> Note that if the diagnosis and score greater than 9 was provided by a non-behavioral health provider, the diagnosis can be in any position.

Appendix DEP-REM-12. Depression Remission at Twelve Months

**Total:**  $42/60 = .70 = .70$  or **70%**

Measure interpretation: Of the Medicaid consumers in the eligible population aged 18 years and older with Major Depression or Dysthymia and an initial PHQ-9 score  $> 9$ , 73% demonstrated remission at twelve months defined as a PHQ-9 score less than 5.

**Appendix HOU: Housing Status**

Percentage of consumers in 10 categories of living situation

**EXAMPLE**

Assuming 100 consumers during the first half of the measurement year (MY) and 120 consumers during the second half of the MY, calculate this metric as follows:

| <b>Living Situation</b>      | <b>First Half of MY (N)</b> | <b>First Half of MY (%)</b> | <b>Second Half of MY (N)</b> | <b>Second Half of MY (%)</b> |
|------------------------------|-----------------------------|-----------------------------|------------------------------|------------------------------|
| Private residence            | 45                          | 45%                         | 49                           | 41%                          |
| Foster home                  | 8                           | 8%                          | 16                           | 13%                          |
| Residential care             | 4                           | 4%                          | 6                            | 5%                           |
| Crisis residence             | 3                           | 3%                          | 4                            | 3%                           |
| Residential treatment center | 5                           | 5%                          | 5                            | 4%                           |
| Institutional setting        | 7                           | 7%                          | 6                            | 5%                           |
| Jail (correctional facility) | 9                           | 9%                          | 9                            | 8%                           |
| Homeless (shelter)           | 15                          | 15%                         | 12                           | 10%                          |
| Other                        | 3                           | 3%                          | 2                            | 2%                           |
| Not available                | 1                           | 1%                          | 11                           | 9%                           |
| <b>Total</b>                 | <b>100</b>                  | <b>100%</b>                 | <b>120</b>                   | <b>100%</b>                  |

Note: Some portion of these assessments will be made at admissions or discharges, and the remainder will be made at the most recent assessment or indication of living situation for the consumer during the measurement period.

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes that may apply to suicide attempts include those pertaining to drug overdoses (designated as “poisonings”), to ingestion of non-drugs (classified as poisoning with a toxic effect), and to other self-inflicted injuries. In addition, codes related to suicidal ideation and suicide attempt are available. Each category is provided below.

**Drug Overdose.** Unlike ICD-9-CM codes, ICD-10-CM codes for poisoning by drug overdose include both the drug poisoning and the circumstances of the poisoning (accidental, intentional, assault, and undetermined). These ICD-10-CM codes are included in code categories T36–T50, with the codes related to intentional overdose listed in Table 1 below.

**Table 1. Suicide Attempt by Intentional Drug Overdose Codes**

| Code    | Poisoning by Overdose  |
|---------|--|
| T360X2A | Poisoning by penicillins, intentional self-harm, initial encounter   |
| T360X2D | Poisoning by penicillins, intentional self-harm, subsequent encounter                                      |
| T360X2S | Poisoning by penicillins, intentional self-harm, sequela   |
| T361X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter    |
| T361X2D | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, subsequent encounter |
| T361X2S | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, sequela              |
| T362X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter                               |
| T362X2D | Poisoning by chloramphenicol group, intentional self-harm, subsequent encounter                            |
| T362X2S | Poisoning by chloramphenicol group, intentional self-harm, sequela   |
| T363X2A | Poisoning by macrolides, intentional self-harm, initial encounter  |
| T363X2D | Poisoning by macrolides, intentional self-harm, subsequent encounter                                       |
| T363X2S | Poisoning by macrolides, intentional self-harm, sequela  |
| T364X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter                                       |
| T364X2D | Poisoning by tetracyclines, intentional self-harm, subsequent encounter                                    |



Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T364X2S     | Poisoning by tetracyclines, intentional self-harm, sequela  |
| T365X2A     | Poisoning by aminoglycosides, intentional self-harm, initial encounter                              |
| T365X2D     | Poisoning by aminoglycosides, intentional self-harm, subsequent encounter                           |
| T365X2S     | Poisoning by aminoglycosides, intentional self-harm, sequela  |
| T366X2A     | Poisoning by rifampicins, intentional self-harm, initial encounter                                  |
| T366X2D     | Poisoning by rifampicins, intentional self-harm, subsequent encounter                               |
| T366X2S     | Poisoning by rifampicins, intentional self-harm, sequela  |
| T367X2A     | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter    |
| T367X2D     | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, subsequent encounter |
| T367X2S     | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, sequela              |
| T368X2A     | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter                   |
| T368X2D     | Poisoning by other systemic antibiotics, intentional self-harm, subsequent encounter                |
| T368X2S     | Poisoning by other systemic antibiotics, intentional self-harm, sequela                             |
| T3692XA     | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter              |
| T3692XD     | Poisoning by unspecified systemic antibiotic, intentional self-harm, subsequent encounter           |
| T3692XS     | Poisoning by unspecified systemic antibiotic, intentional self-harm, sequela                        |
| T370X2A     | Poisoning by sulfonamides, intentional self-harm, initial encounter                                 |
| T370X2D     | Poisoning by sulfonamides, intentional self-harm, subsequent encounter                              |
| T370X2S     | Poisoning by sulfonamides, intentional self-harm, sequela   |
| T371X2A     | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter                      |
| T371X2D     | Poisoning by antimycobacterial drugs, intentional self-harm, subsequent encounter                   |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T371X2S     | Poisoning by antimycobacterial drugs, intentional self-harm, sequela  |
| T372X2A     | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter         |
| T372X2D     | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, subsequent encounter      |
| T372X2S     | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, sequela                   |
| T374X2A     | Poisoning by anthelmintics, intentional self-harm, initial encounter  |
| T374X2D     | Poisoning by anthelmintics, intentional self-harm, subsequent encounter   |
| T374X2S     | Poisoning by anthelmintics, intentional self-harm, sequela  |
| T375X2A     | Poisoning by antiviral drugs, intentional self-harm, initial encounter  |
| T375X2D     | Poisoning by antiviral drugs, intentional self-harm, subsequent encounter   |
| T375X2S     | Poisoning by antiviral drugs, intentional self-harm, sequela  |
| T378X2A     | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter    |
| T378X2D     | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter |
| T378X2S     | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela              |
| T3792XA     | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter         |
| T3792XD     | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, subsequent encounter      |
| T3792XS     | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, sequela                   |
| T380X2A     | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter                        |
| T380X2D     | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, subsequent encounter                     |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T380X2S     | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, sequela   |
| T381X2A     | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter  |
| T381X2D     | Poisoning by thyroid hormones and substitutes, intentional self-harm, subsequent encounter   |
| T381X2S     | Poisoning by thyroid hormones and substitutes, intentional self-harm, sequela  |
| T382X2A     | Poisoning by antithyroid drugs, intentional self-harm, initial encounter   |
| T382X2D     | Poisoning by antithyroid drugs, intentional self-harm, subsequent encounter  |
| T382X2S     | Poisoning by antithyroid drugs, intentional self-harm, sequela   |
| T383X2A     | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, initial encounter                            |
| T383X2D     | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, subsequent encounter                         |
| T383X2S     | Poisoning by insulin and oral hypoglycemic [antidiabetic] drugs, intentional self-harm, sequela                                      |
| T384X2A     | Poisoning by oral contraceptives, intentional self-harm, initial encounter   |
| T384X2D     | Poisoning by oral contraceptives, intentional self-harm, subsequent encounter  |
| T384X2S     | Poisoning by oral contraceptives, intentional self-harm, sequela   |
| T385X2A     | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter  |
| T385X2D     | Poisoning by other estrogens and progestogens, intentional self-harm, subsequent encounter   |
| T385X2S     | Poisoning by other estrogens and progestogens, intentional self-harm, sequela  |
| T386X2A     | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter    |
| T386X2D     | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, subsequent encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T386X2S     | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, sequela |
| T387X2A     | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter                                 |
| T387X2D     | Poisoning by androgens and anabolic congeners, intentional self-harm, subsequent encounter                              |
| T387X2S     | Poisoning by androgens and anabolic congeners, intentional self-harm, sequela   |
| T38802A     | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter                   |
| T38802D     | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, subsequent encounter                |
| T38802S     | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, sequela                             |
| T38812A     | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, initial encounter                   |
| T38812D     | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, subsequent encounter                |
| T38812S     | Poisoning by anterior pituitary [adenohypophyseal] hormones, intentional self-harm, sequela                             |
| T38892A     | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter                         |
| T38892D     | Poisoning by other hormones and synthetic substitutes, intentional self-harm, subsequent encounter                      |
| T38892S     | Poisoning by other hormones and synthetic substitutes, intentional self-harm, sequela                                   |
| T38902A     | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter                                  |
| T38902D     | Poisoning by unspecified hormone antagonists, intentional self-harm, subsequent encounter                               |
| T38902S     | Poisoning by unspecified hormone antagonists, intentional self-harm, sequela  |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T38992A     | Poisoning by other hormone antagonists, intentional self-harm, initial encounter                             |
| T38992D     | Poisoning by other hormone antagonists, intentional self-harm, subsequent encounter                          |
| T38992S     | Poisoning by other hormone antagonists, intentional self-harm, sequela                                       |
| T39012A     | Poisoning by aspirin, intentional self-harm, initial encounter   |
| T39012D     | Poisoning by aspirin, intentional self-harm, subsequent encounter  |
| T39012S     | Poisoning by aspirin, intentional self-harm, sequela   |
| T39092A     | Poisoning by salicylates, intentional self-harm, initial encounter   |
| T39092D     | Poisoning by salicylates, intentional self-harm, subsequent encounter  |
| T39092S     | Poisoning by salicylates, intentional self-harm, sequela   |
| T391X2A     | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter                             |
| T391X2D     | Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter                          |
| T391X2S     | Poisoning by 4-Aminophenol derivatives, intentional self-harm, sequela                                       |
| T392X2A     | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter                                |
| T392X2D     | Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter                             |
| T392X2S     | Poisoning by pyrazolone derivatives, intentional self-harm, sequela  |
| T39312A     | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter                            |
| T39312D     | Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter                         |
| T39312S     | Poisoning by propionic acid derivatives, intentional self-harm, sequela                                      |
| T39392A     | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter    |
| T39392D     | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter |
| T39392S     | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, sequela              |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T394X2A     | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter                                 |
| T394X2D     | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, subsequent encounter                              |
| T394X2S     | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, sequela   |
| T398X2A     | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter    |
| T398X2D     | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, subsequent encounter |
| T398X2S     | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, sequela              |
| T3992XA     | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter           |
| T3992XD     | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, subsequent encounter        |
| T3992XS     | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, sequela                     |
| T400X2A     | Poisoning by opium, intentional self-harm, initial encounter  |
| T400X2D     | Poisoning by opium, intentional self-harm, subsequent encounter   |
| T400X2S     | Poisoning by opium, intentional self-harm, sequela  |
| T401X2A     | Poisoning by heroin, intentional self-harm, initial encounter   |
| T401X2D     | Poisoning by heroin, intentional self-harm, subsequent encounter  |
| T401X2S     | Poisoning by heroin, intentional self-harm, sequela   |
| T402X2A     | Poisoning by other opioids, intentional self-harm, initial encounter  |
| T402X2D     | Poisoning by other opioids, intentional self-harm, subsequent encounter   |
| T402X2S     | Poisoning by other opioids, intentional self-harm, sequela  |
| T403X2A     | Poisoning by methadone, intentional self-harm, initial encounter  |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T403X2D     | Poisoning by methadone, intentional self-harm, subsequent encounter                                    |
| T403X2S     | Poisoning by methadone, intentional self-harm, sequela   |
| T404X2A     | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter                       |
| T404X2D     | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter                    |
| T404X2S     | Poisoning by other synthetic narcotics, intentional self-harm, sequela                                 |
| T405X2A     | Poisoning by cocaine, intentional self-harm, initial encounter   |
| T405X2D     | Poisoning by cocaine, intentional self-harm, subsequent encounter                                      |
| T405X2S     | Poisoning by cocaine, intentional self-harm, sequela   |
| T40602A     | Poisoning by unspecified narcotics, intentional self-harm, initial encounter                           |
| T40602D     | Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter                        |
| T40602S     | Poisoning by unspecified narcotics, intentional self-harm, sequela                                     |
| T40692A     | Poisoning by other narcotics, intentional self-harm, initial encounter                                 |
| T40692D     | Poisoning by other narcotics, intentional self-harm, subsequent encounter                              |
| T40692S     | Poisoning by other narcotics, intentional self-harm, sequela   |
| T407X2A     | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter                          |
| T407X2D     | Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter                       |
| T407X2S     | Poisoning by cannabis (derivatives), intentional self-harm, sequela                                    |
| T408X2A     | Poisoning by lysergide [LSD], intentional self-harm, initial encounter                                 |
| T408X2D     | Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter                              |
| T408X2S     | Poisoning by lysergide [LSD], intentional self-harm, sequela   |
| T40902A     | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter    |
| T40902D     | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T40902S     | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, sequela        |
| T40992A     | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter    |
| T40992D     | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter |
| T40992S     | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, sequela              |
| T410X2A     | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter                       |
| T410X2D     | Poisoning by inhaled anesthetics, intentional self-harm, subsequent encounter                    |
| T410X2S     | Poisoning by inhaled anesthetics, intentional self-harm, sequela                                 |
| T411X2A     | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter                   |
| T411X2D     | Poisoning by intravenous anesthetics, intentional self-harm, subsequent encounter                |
| T411X2S     | Poisoning by intravenous anesthetics, intentional self-harm, sequela                             |
| T41202A     | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter           |
| T41202D     | Poisoning by unspecified general anesthetics, intentional self-harm, subsequent encounter        |
| T41202S     | Poisoning by unspecified general anesthetics, intentional self-harm, sequela                     |
| T41292A     | Poisoning by other general anesthetics, intentional self-harm, initial encounter                 |
| T41292D     | Poisoning by other general anesthetics, intentional self-harm, subsequent encounter              |
| T41292S     | Poisoning by other general anesthetics, intentional self-harm, sequela                           |
| T413X2A     | Poisoning by local anesthetics, intentional self-harm, initial encounter                         |
| T413X2D     | Poisoning by local anesthetics, intentional self-harm, subsequent encounter                      |
| T413X2S     | Poisoning by local anesthetics, intentional self-harm, sequela                                   |
| T4142XA     | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter                    |



## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T4142XD     | Poisoning by unspecified anesthetic, intentional self-harm, subsequent encounter             |
| T4142XS     | Poisoning by unspecified anesthetic, intentional self-harm, sequela                          |
| T415X2A     | Poisoning by therapeutic gases, intentional self-harm, initial encounter                     |
| T415X2D     | Poisoning by therapeutic gases, intentional self-harm, subsequent encounter                  |
| T415X2S     | Poisoning by therapeutic gases, intentional self-harm, sequela                               |
| T420X2A     | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter                 |
| T420X2D     | Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter              |
| T420X2S     | Poisoning by hydantoin derivatives, intentional self-harm, sequela                           |
| T421X2A     | Poisoning by iminostilbenes, intentional self-harm, initial encounter                        |
| T421X2D     | Poisoning by iminostilbenes, intentional self-harm, subsequent encounter                     |
| T421X2S     | Poisoning by iminostilbenes, intentional self-harm, sequela                                  |
| T422X2A     | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter    |
| T422X2D     | Poisoning by succinimides and oxazolidinediones, intentional self-harm, subsequent encounter |
| T422X2S     | Poisoning by succinimides and oxazolidinediones, intentional self-harm, sequela              |
| T423X2A     | Poisoning by barbiturates, intentional self-harm, initial encounter                          |
| T423X2D     | Poisoning by barbiturates, intentional self-harm, subsequent encounter                       |
| T423X2S     | Poisoning by barbiturates, intentional self-harm, sequela                                    |
| T424X2A     | Poisoning by benzodiazepines, intentional self-harm, initial encounter                       |
| T424X2D     | Poisoning by benzodiazepines, intentional self-harm, subsequent encounter                    |
| T424X2S     | Poisoning by benzodiazepines, intentional self-harm, sequela                                 |
| T425X2A     | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter                  |
| T425X2D     | Poisoning by mixed antiepileptics, intentional self-harm, subsequent encounter               |
| T425X2S     | Poisoning by mixed antiepileptics, intentional self-harm, sequela                            |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T426X2A     | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter                     |
| T426X2D     | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter                  |
| T426X2S     | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela                               |
| T4272XA     | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter               |
| T4272XD     | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter            |
| T4272XS     | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, sequela                         |
| T428X2A     | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter    |
| T428X2D     | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, subsequent encounter |
| T428X2S     | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, sequela              |
| T43012A     | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter   |
| T43012D     | Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter  |
| T43012S     | Poisoning by tricyclic antidepressants, intentional self-harm, sequela   |
| T43022A     | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter   |
| T43022D     | Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter                                      |
| T43022S     | Poisoning by tetracyclic antidepressants, intentional self-harm, sequela   |
| T431X2A     | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter                         |
| T431X2D     | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter                      |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T431X2S     | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, sequela                             |
| T43202A     | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter                                   |
| T43202D     | Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter                                |
| T43202S     | Poisoning by unspecified antidepressants, intentional self-harm, sequela   |
| T43212A     | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter    |
| T43212D     | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter |
| T43212S     | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, sequela              |
| T43222A     | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter                       |
| T43222D     | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter                    |
| T43222S     | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, sequela                                 |
| T43292A     | Poisoning by other antidepressants, intentional self-harm, initial encounter   |
| T43292D     | Poisoning by other antidepressants, intentional self-harm, subsequent encounter                                      |
| T43292S     | Poisoning by other antidepressants, intentional self-harm, sequela   |
| T43592A     | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter                         |
| T43592D     | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter                      |
| T43592S     | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, sequela                                   |
| T43602A     | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter                                  |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T43602D     | Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter  |
| T43602S     | Poisoning by unspecified psychostimulants, intentional self-harm, sequela               |
| T43612A     | Poisoning by caffeine, intentional self-harm, initial encounter                         |
| T43612D     | Poisoning by caffeine, intentional self-harm, subsequent encounter                      |
| T43612S     | Poisoning by caffeine, intentional self-harm, sequela                                   |
| T43613A     | Poisoning by caffeine, assault, initial encounter                                       |
| T43622A     | Poisoning by amphetamines, intentional self-harm, initial encounter                     |
| T43622D     | Poisoning by amphetamines, intentional self-harm, subsequent encounter                  |
| T43622S     | Poisoning by amphetamines, intentional self-harm, sequela                               |
| T43632A     | Poisoning by methylphenidate, intentional self-harm, initial encounter                  |
| T43632D     | Poisoning by methylphenidate, intentional self-harm, subsequent encounter               |
| T43632S     | Poisoning by methylphenidate, intentional self-harm, sequela                            |
| T43692A     | Poisoning by other psychostimulants, intentional self-harm, initial encounter           |
| T43692D     | Poisoning by other psychostimulants, intentional self-harm, subsequent encounter        |
| T43692S     | Poisoning by other psychostimulants, intentional self-harm, sequela                     |
| T438X2A     | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter         |
| T438X2D     | Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter      |
| T438X2S     | Poisoning by other psychotropic drugs, intentional self-harm, sequela                   |
| T4392XA     | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter    |
| T4392XD     | Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter |
| T4392XS     | Poisoning by unspecified psychotropic drug, intentional self-harm, sequela              |
| T440X2A     | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter        |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T440X2D     | Poisoning by anticholinesterase agents, intentional self-harm, subsequent encounter  |
| T440X2S     | Poisoning by anticholinesterase agents, intentional self-harm, sequela   |
| T441X2A     | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter   |
| T441X2D     | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter  |
| T441X2S     | Poisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela   |
| T442X2A     | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter   |
| T442X2D     | Poisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter  |
| T442X2S     | Poisoning by ganglionic blocking drugs, intentional self-harm, sequela   |
| T443X2A     | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter    |
| T443X2D     | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter |
| T443X2S     | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela              |
| T444X2A     | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter   |
| T444X2D     | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter                                      |
| T444X2S     | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela   |
| T445X2A     | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter  |
| T445X2D     | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter                                       |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T445X2S     | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela                                      |
| T446X2A     | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter                                      |
| T446X2D     | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter                                   |
| T446X2S     | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela  |
| T447X2A     | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter                                       |
| T447X2D     | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter                                    |
| T447X2S     | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela   |
| T448X2A     | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter                |
| T448X2D     | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter             |
| T448X2S     | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela                          |
| T44902A     | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter    |
| T44902D     | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter |
| T44902S     | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela              |
| T44992A     | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter           |
| T44992D     | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter        |
| T44992S     | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela                     |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T450X2A     | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter             |
| T450X2D     | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter          |
| T450X2S     | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, sequela                       |
| T451X2A     | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter    |
| T451X2D     | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter |
| T451X2S     | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, sequela              |
| T452X2A     | Poisoning by vitamins, intentional self-harm, initial encounter                                      |
| T452X2D     | Poisoning by vitamins, intentional self-harm, subsequent encounter                                   |
| T452X2S     | Poisoning by vitamins, intentional self-harm, sequela  |
| T453X2A     | Poisoning by enzymes, intentional self-harm, initial encounter                                       |
| T453X2D     | Poisoning by enzymes, intentional self-harm, subsequent encounter                                    |
| T453X2S     | Poisoning by enzymes, intentional self-harm, sequela   |
| T454X2A     | Poisoning by iron and its compounds, intentional self-harm, initial encounter                        |
| T454X2D     | Poisoning by iron and its compounds, intentional self-harm, subsequent encounter                     |
| T454X2S     | Poisoning by iron and its compounds, intentional self-harm, sequela                                  |
| T45512A     | Poisoning by anticoagulants, intentional self-harm, initial encounter                                |
| T45512D     | Poisoning by anticoagulants, intentional self-harm, subsequent encounter                             |
| T45512S     | Poisoning by anticoagulants, intentional self-harm, sequela  |
| T45522A     | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter                          |
| T45522D     | Poisoning by antithrombotic drugs, intentional self-harm, subsequent encounter                       |
| T45522S     | Poisoning by antithrombotic drugs, intentional self-harm, sequela                                    |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T45602A     | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter                     |
| T45602D     | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter                  |
| T45602S     | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, sequela                               |
| T45612A     | Poisoning by thrombolytic drug, intentional self-harm, initial encounter  |
| T45612D     | Poisoning by thrombolytic drug, intentional self-harm, subsequent encounter   |
| T45612S     | Poisoning by thrombolytic drug, intentional self-harm, sequela  |
| T45622A     | Poisoning by hemostatic drug, intentional self-harm, initial encounter  |
| T45622D     | Poisoning by hemostatic drug, intentional self-harm, subsequent encounter   |
| T45622S     | Poisoning by hemostatic drug, intentional self-harm, sequela  |
| T45692A     | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter                           |
| T45692D     | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter                        |
| T45692S     | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, sequela                                     |
| T457X2A     | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter    |
| T457X2D     | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter |
| T457X2S     | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, sequela              |
| T458X2A     | Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter            |
| T458X2D     | Poisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter         |
| T458X2S     | Poisoning by other primarily systemic and hematological agents, intentional self-harm, sequela                      |



Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T4592XA     | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter      |
| T4592XD     | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter   |
| T4592XS     | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, sequela                |
| T460X2A     | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter    |
| T460X2D     | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter |
| T460X2S     | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, sequela              |
| T461X2A     | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter                                    |
| T461X2D     | Poisoning by calcium-channel blockers, intentional self-harm, subsequent encounter                                 |
| T461X2S     | Poisoning by calcium-channel blockers, intentional self-harm, sequela  |
| T462X2A     | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter                                 |
| T462X2D     | Poisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter                              |
| T462X2S     | Poisoning by other antidysrhythmic drugs, intentional self-harm, sequela   |
| T463X2A     | Poisoning by coronary vasodilators, intentional self-harm, initial encounter                                       |
| T463X2D     | Poisoning by coronary vasodilators, intentional self-harm, subsequent encounter                                    |
| T463X2S     | Poisoning by coronary vasodilators, intentional self-harm, sequela   |
| T464X2A     | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter                    |
| T464X2D     | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter                 |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T464X2S     | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, sequela                                      |
| T465X2A     | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter  |
| T465X2D     | Poisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter                                     |
| T465X2S     | Poisoning by other antihypertensive drugs, intentional self-harm, sequela  |
| T466X2A     | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter                   |
| T466X2D     | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter                |
| T466X2S     | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, sequela                             |
| T467X2A     | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter   |
| T467X2D     | Poisoning by peripheral vasodilators, intentional self-harm, subsequent encounter  |
| T467X2S     | Poisoning by peripheral vasodilators, intentional self-harm, sequela   |
| T468X2A     | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter                     |
| T468X2D     | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter                  |
| T468X2S     | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, sequela                               |
| T46902A     | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter    |
| T46902D     | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter |
| T46902S     | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, sequela              |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T46992A     | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter    |
| T46992D     | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter |
| T46992S     | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, sequela              |
| T470X2A     | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter                                |
| T470X2D     | Poisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter                             |
| T470X2S     | Poisoning by histamine H2-receptor blockers, intentional self-harm, sequela  |
| T471X2A     | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter               |
| T471X2D     | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter            |
| T471X2S     | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, sequela                         |
| T472X2A     | Poisoning by stimulant laxatives, intentional self-harm, initial encounter   |
| T472X2D     | Poisoning by stimulant laxatives, intentional self-harm, subsequent encounter  |
| T472X2S     | Poisoning by stimulant laxatives, intentional self-harm, sequela   |
| T473X2A     | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter                                  |
| T473X2D     | Poisoning by saline and osmotic laxatives, intentional self-harm, subsequent encounter                               |
| T473X2S     | Poisoning by saline and osmotic laxatives, intentional self-harm, sequela  |
| T474X2A     | Poisoning by other laxatives, intentional self-harm, initial encounter   |
| T474X2D     | Poisoning by other laxatives, intentional self-harm, subsequent encounter  |
| T474X2S     | Poisoning by other laxatives, intentional self-harm, sequela   |
| T475X2A     | Poisoning by digestants, intentional self-harm, initial encounter  |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T475X2D     | Poisoning by digestants, intentional self-harm, subsequent encounter   |
| T475X2S     | Poisoning by digestants, intentional self-harm, sequela  |
| T476X2A     | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter   |
| T476X2D     | Poisoning by antidiarrheal drugs, intentional self-harm, subsequent encounter  |
| T476X2S     | Poisoning by antidiarrheal drugs, intentional self-harm, sequela   |
| T477X2A     | Poisoning by emetics, intentional self-harm, initial encounter   |
| T477X2D     | Poisoning by emetics, intentional self-harm, subsequent encounter  |
| T477X2S     | Poisoning by emetics, intentional self-harm, sequela   |
| T478X2A     | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter              |
| T478X2D     | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, subsequent encounter           |
| T478X2S     | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, sequela                        |
| T4792XA     | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter    |
| T4792XD     | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, subsequent encounter |
| T4792XS     | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, sequela              |
| T480X2A     | Poisoning by oxytocic drugs, intentional self-harm, initial encounter  |
| T480X2D     | Poisoning by oxytocic drugs, intentional self-harm, subsequent encounter   |
| T480X2S     | Poisoning by oxytocic drugs, intentional self-harm, sequela  |
| T481X2A     | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, initial encounter             |
| T481X2D     | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, subsequent encounter          |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T481X2S     | Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], intentional self-harm, sequela               |
| T48202A     | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter                           |
| T48202D     | Poisoning by unspecified drugs acting on muscles, intentional self-harm, subsequent encounter                        |
| T48202S     | Poisoning by unspecified drugs acting on muscles, intentional self-harm, sequela                                     |
| T48292A     | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter                                 |
| T48292D     | Poisoning by other drugs acting on muscles, intentional self-harm, subsequent encounter                              |
| T48292S     | Poisoning by other drugs acting on muscles, intentional self-harm, sequela   |
| T483X2A     | Poisoning by antitussives, intentional self-harm, initial encounter  |
| T483X2D     | Poisoning by antitussives, intentional self-harm, subsequent encounter   |
| T483X2S     | Poisoning by antitussives, intentional self-harm, sequela  |
| T484X2A     | Poisoning by expectorants, intentional self-harm, initial encounter  |
| T484X2D     | Poisoning by expectorants, intentional self-harm, subsequent encounter   |
| T484X2S     | Poisoning by expectorants, intentional self-harm, sequela  |
| T485X2A     | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter                                  |
| T485X2D     | Poisoning by other anti-common-cold drugs, intentional self-harm, subsequent encounter                               |
| T485X2S     | Poisoning by other anti-common-cold drugs, intentional self-harm, sequela  |
| T486X2A     | Poisoning by antiasthmatics, intentional self-harm, initial encounter  |
| T486X2D     | Poisoning by antiasthmatics, intentional self-harm, subsequent encounter   |
| T486X2S     | Poisoning by antiasthmatics, intentional self-harm, sequela  |
| T48902A     | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T48902D     | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter |
| T48902S     | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, sequela              |
| T48992A     | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter          |
| T48992D     | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, subsequent encounter       |
| T48992S     | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, sequela                    |
| T490X2A     | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter     |
| T490X2D     | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, subsequent encounter  |
| T490X2S     | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, sequela               |
| T491X2A     | Poisoning by antipruritics, intentional self-harm, initial encounter  |
| T491X2D     | Poisoning by antipruritics, intentional self-harm, subsequent encounter   |
| T491X2S     | Poisoning by antipruritics, intentional self-harm, sequela  |
| T492X2A     | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter                           |
| T492X2D     | Poisoning by local astringents and local detergents, intentional self-harm, subsequent encounter                        |
| T492X2S     | Poisoning by local astringents and local detergents, intentional self-harm, sequela                                     |
| T493X2A     | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter                           |
| T493X2D     | Poisoning by emollients, demulcents and protectants, intentional self-harm, subsequent encounter                        |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>  |
|-------------|---|
| T493X2S     | Poisoning by emollients, demulcents and protectants, intentional self-harm, sequela   |
| T494X2A     | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter    |
| T494X2D     | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, subsequent encounter |
| T494X2S     | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, sequela              |
| T495X2A     | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter  |
| T495X2D     | Poisoning by ophthalmological drugs and preparations, intentional self-harm, subsequent encounter                                       |
| T495X2S     | Poisoning by ophthalmological drugs and preparations, intentional self-harm, sequela  |
| T496X2A     | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter                                    |
| T496X2D     | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, subsequent encounter                                 |
| T496X2S     | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, sequela  |
| T497X2A     | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter  |
| T497X2D     | Poisoning by dental drugs, topically applied, intentional self-harm, subsequent encounter   |
| T497X2S     | Poisoning by dental drugs, topically applied, intentional self-harm, sequela  |
| T498X2A     | Poisoning by other topical agents, intentional self-harm, initial encounter   |
| T498X2D     | Poisoning by other topical agents, intentional self-harm, subsequent encounter  |
| T498X2S     | Poisoning by other topical agents, intentional self-harm, sequela   |
| T4992XA     | Poisoning by unspecified topical agent, intentional self-harm, initial encounter  |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T4992XD     | Poisoning by unspecified topical agent, intentional self-harm, subsequent encounter  |
| T4992XS     | Poisoning by unspecified topical agent, intentional self-harm, sequela   |
| T500X2A     | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter                                |
| T500X2D     | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, subsequent encounter                             |
| T500X2S     | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, sequela  |
| T501X2A     | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, initial encounter   |
| T501X2D     | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, subsequent encounter  |
| T501X2S     | Poisoning by loop [high-ceiling] diuretics, intentional self-harm, sequela   |
| T502X2A     | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter    |
| T502X2D     | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, subsequent encounter |
| T502X2S     | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, sequela              |
| T503X2A     | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter                          |
| T503X2D     | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, subsequent encounter                       |
| T503X2S     | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, sequela                                    |
| T504X2A     | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter                                    |
| T504X2D     | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, subsequent encounter                                 |



Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T504X2S     | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, sequela                                  |
| T505X2A     | Poisoning by appetite depressants, intentional self-harm, initial encounter  |
| T505X2D     | Poisoning by appetite depressants, intentional self-harm, subsequent encounter                                     |
| T505X2S     | Poisoning by appetite depressants, intentional self-harm, sequela  |
| T506X2A     | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter                              |
| T506X2D     | Poisoning by antidotes and chelating agents, intentional self-harm, subsequent encounter                           |
| T506X2S     | Poisoning by antidotes and chelating agents, intentional self-harm, sequela  |
| T507X2A     | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter                  |
| T507X2D     | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, subsequent encounter               |
| T507X2S     | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, sequela                            |
| T508X2A     | Poisoning by diagnostic agents, intentional self-harm, initial encounter   |
| T508X2D     | Poisoning by diagnostic agents, intentional self-harm, subsequent encounter  |
| T508X2S     | Poisoning by diagnostic agents, intentional self-harm, sequela   |
| T50902A     | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter    |
| T50902D     | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter |
| T50902S     | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, sequela              |
| T50992A     | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter          |
| T50992D     | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter       |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T50992S     | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, sequela                                |
| T50A12A     | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter    |
| T50A12D     | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, subsequent encounter |
| T50A12S     | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, sequela              |
| T50A22A     | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter                  |
| T50A22D     | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, subsequent encounter               |
| T50A22S     | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, sequela                            |
| T50A92A     | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter  |
| T50A92D     | Poisoning by other bacterial vaccines, intentional self-harm, subsequent encounter   |
| T50A92S     | Poisoning by other bacterial vaccines, intentional self-harm, sequela  |
| T50B12A     | Poisoning by smallpox vaccines, intentional self-harm, initial encounter   |
| T50B12D     | Poisoning by smallpox vaccines, intentional self-harm, subsequent encounter  |
| T50B12S     | Poisoning by smallpox vaccines, intentional self-harm, sequela   |
| T50B92A     | Poisoning by other viral vaccines, intentional self-harm, initial encounter  |
| T50B92D     | Poisoning by other viral vaccines, intentional self-harm, subsequent encounter   |
| T50B92S     | Poisoning by other viral vaccines, intentional self-harm, sequela  |
| T50Z12A     | Poisoning by immunoglobulin, intentional self-harm, initial encounter  |
| T50Z12D     | Poisoning by immunoglobulin, intentional self-harm, subsequent encounter   |
| T50Z12S     | Poisoning by immunoglobulin, intentional self-harm, sequela  |

| <b>Code</b> | <b>Poisoning by Overdose</b>   |
|-------------|--|
| T50Z92A     | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter    |
| T50Z92D     | Poisoning by other vaccines and biological substances, intentional self-harm, subsequent encounter |
| T50Z92S     | Poisoning by other vaccines and biological substances, intentional self-harm, sequela              |

**Intentional Toxic Exposure.** ICD-10-CM codes for poisoning by toxic exposure, primarily from nonmedicinal substances, are similar to those for drugs; they are categorized as accidental, intentional, assault, and undetermined, and are coded in categories T51-T65. The codes related to intentional poisoning are listed in Table 2 below.

**Table 2. Suicide Attempt by Intentional Toxic Exposure Codes**

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T510X2A     | Toxic effect of ethanol, intentional self-harm, initial encounter           |
| T510X2D     | Toxic effect of ethanol, intentional self-harm, subsequent encounter        |
| T510X2S     | Toxic effect of ethanol, intentional self-harm, sequela                     |
| T511X2A     | Toxic effect of methanol, intentional self-harm, initial encounter          |
| T511X2D     | Toxic effect of methanol, intentional self-harm, subsequent encounter       |
| T511X2S     | Toxic effect of methanol, intentional self-harm, sequela                    |
| T512X2A     | Toxic effect of 2-Propanol, intentional self-harm, initial encounter        |
| T512X2D     | Toxic effect of 2-Propanol, intentional self-harm, subsequent encounter     |
| T512X2S     | Toxic effect of 2-Propanol, intentional self-harm, sequela                  |
| T513X2A     | Toxic effect of fusel oil, intentional self-harm, initial encounter         |
| T513X2D     | Toxic effect of fusel oil, intentional self-harm, subsequent encounter      |
| T513X2S     | Toxic effect of fusel oil, intentional self-harm, sequela                   |
| T518X2A     | Toxic effect of other alcohols, intentional self-harm, initial encounter    |
| T518X2D     | Toxic effect of other alcohols, intentional self-harm, subsequent encounter |
| T518X2S     | Toxic effect of other alcohols, intentional self-harm, sequela              |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T5192XA     | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter         |
| T5192XD     | Toxic effect of unspecified alcohol, intentional self-harm, subsequent encounter      |
| T5192XS     | Toxic effect of unspecified alcohol, intentional self-harm, sequela                   |
| T520X2A     | Toxic effect of petroleum products, intentional self-harm, initial encounter          |
| T520X2D     | Toxic effect of petroleum products, intentional self-harm, subsequent encounter       |
| T520X2S     | Toxic effect of petroleum products, intentional self-harm, sequela                    |
| T521X2A     | Toxic effect of benzene, intentional self-harm, initial encounter                     |
| T521X2D     | Toxic effect of benzene, intentional self-harm, subsequent encounter                  |
| T521X2S     | Toxic effect of benzene, intentional self-harm, sequela                               |
| T522X2A     | Toxic effect of homologues of benzene, intentional self-harm, initial encounter       |
| T522X2D     | Toxic effect of homologues of benzene, intentional self-harm, subsequent encounter    |
| T522X2S     | Toxic effect of homologues of benzene, intentional self-harm, sequela                 |
| T523X2A     | Toxic effect of glycols, intentional self-harm, initial encounter                     |
| T523X2D     | Toxic effect of glycols, intentional self-harm, subsequent encounter                  |
| T523X2S     | Toxic effect of glycols, intentional self-harm, sequela                               |
| T524X2A     | Toxic effect of ketones, intentional self-harm, initial encounter                     |
| T524X2D     | Toxic effect of ketones, intentional self-harm, subsequent encounter                  |
| T524X2S     | Toxic effect of ketones, intentional self-harm, sequela                               |
| T528X2A     | Toxic effect of other organic solvents, intentional self-harm, initial encounter      |
| T528X2D     | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter   |
| T528X2S     | Toxic effect of other organic solvents, intentional self-harm, sequela                |
| T5292XA     | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T5292XD     | Toxic effect of unspecified organic solvent, intentional self-harm, subsequent encounter                         |
| T5292XS     | Toxic effect of unspecified organic solvent, intentional self-harm, sequela                                      |
| T530X2A     | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter                                   |
| T530X2D     | Toxic effect of carbon tetrachloride, intentional self-harm, subsequent encounter                                |
| T530X2S     | Toxic effect of carbon tetrachloride, intentional self-harm, sequela   |
| T531X2A     | Toxic effect of chloroform, intentional self-harm, initial encounter   |
| T531X2D     | Toxic effect of chloroform, intentional self-harm, subsequent encounter  |
| T531X2S     | Toxic effect of chloroform, intentional self-harm, sequela   |
| T532X2A     | Toxic effect of trichloroethylene, intentional self-harm, initial encounter                                      |
| T532X2D     | Toxic effect of trichloroethylene, intentional self-harm, subsequent encounter                                   |
| T532X2S     | Toxic effect of trichloroethylene, intentional self-harm, sequela  |
| T533X2A     | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter                                    |
| T533X2D     | Toxic effect of tetrachloroethylene, intentional self-harm, subsequent encounter                                 |
| T533X2S     | Toxic effect of tetrachloroethylene, intentional self-harm, sequela  |
| T534X2A     | Toxic effect of dichloromethane, intentional self-harm, initial encounter  |
| T534X2D     | Toxic effect of dichloromethane, intentional self-harm, subsequent encounter                                     |
| T534X2S     | Toxic effect of dichloromethane, intentional self-harm, sequela  |
| T535X2A     | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter                                    |
| T535X2D     | Toxic effect of chlorofluorocarbons, intentional self-harm, subsequent encounter                                 |
| T535X2S     | Toxic effect of chlorofluorocarbons, intentional self-harm, sequela  |
| T536X2A     | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter    |
| T536X2D     | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, subsequent encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T536X2S     | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, sequela                                 |
| T537X2A     | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter                        |
| T537X2D     | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, subsequent encounter                     |
| T537X2S     | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, sequela                                  |
| T5392XA     | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter    |
| T5392XD     | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, subsequent encounter |
| T5392XS     | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, sequela              |
| T540X2A     | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter  |
| T540X2D     | Toxic effect of phenol and phenol homologues, intentional self-harm, subsequent encounter   |
| T540X2S     | Toxic effect of phenol and phenol homologues, intentional self-harm, sequela  |
| T541X2A     | Toxic effect of other corrosive organic compounds, intentional self-harm, initial encounter   |
| T541X2D     | Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter                                      |
| T541X2S     | Toxic effect of other corrosive organic compounds, intentional self-harm, sequela   |
| T542X2A     | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter                                  |
| T542X2D     | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter                               |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T542X2S     | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela                  |
| T543X2A     | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter    |
| T543X2D     | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter |
| T543X2S     | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela              |
| T5492XA     | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter                 |
| T5492XD     | Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter              |
| T5492XS     | Toxic effect of unspecified corrosive substance, intentional self-harm, sequela                           |
| T550X2A     | Toxic effect of soaps, intentional self-harm, initial encounter   |
| T550X2D     | Toxic effect of soaps, intentional self-harm, subsequent encounter  |
| T550X2S     | Toxic effect of soaps, intentional self-harm, sequela   |
| T551X2A     | Toxic effect of detergents, intentional self-harm, initial encounter                                      |
| T551X2D     | Toxic effect of detergents, intentional self-harm, subsequent encounter                                   |
| T551X2S     | Toxic effect of detergents, intentional self-harm, sequela  |
| T560X2A     | Toxic effect of lead and its compounds, intentional self-harm, initial encounter                          |
| T560X2D     | Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter                       |
| T560X2S     | Toxic effect of lead and its compounds, intentional self-harm, sequela                                    |
| T561X2A     | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter                       |
| T561X2D     | Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter                    |
| T561X2S     | Toxic effect of mercury and its compounds, intentional self-harm, sequela                                 |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T562X2A     | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter     |
| T562X2D     | Toxic effect of chromium and its compounds, intentional self-harm, subsequent encounter  |
| T562X2S     | Toxic effect of chromium and its compounds, intentional self-harm, sequela               |
| T563X2A     | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter      |
| T563X2D     | Toxic effect of cadmium and its compounds, intentional self-harm, subsequent encounter   |
| T563X2S     | Toxic effect of cadmium and its compounds, intentional self-harm, sequela                |
| T564X2A     | Toxic effect of copper and its compounds, intentional self-harm, initial encounter       |
| T564X2D     | Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter    |
| T564X2S     | Toxic effect of copper and its compounds, intentional self-harm, sequela                 |
| T565X2A     | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter         |
| T565X2D     | Toxic effect of zinc and its compounds, intentional self-harm, subsequent encounter      |
| T565X2S     | Toxic effect of zinc and its compounds, intentional self-harm, sequela                   |
| T566X2A     | Toxic effect of tin and its compounds, intentional self-harm, initial encounter          |
| T566X2D     | Toxic effect of tin and its compounds, intentional self-harm, subsequent encounter       |
| T566X2S     | Toxic effect of tin and its compounds, intentional self-harm, sequela                    |
| T567X2A     | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter    |
| T567X2D     | Toxic effect of beryllium and its compounds, intentional self-harm, subsequent encounter |
| T567X2S     | Toxic effect of beryllium and its compounds, intentional self-harm, sequela              |
| T56812A     | Toxic effect of thallium, intentional self-harm, initial encounter                       |



## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T56812D     | Toxic effect of thallium, intentional self-harm, subsequent encounter                          |
| T56812S     | Toxic effect of thallium, intentional self-harm, sequela                                       |
| T56892A     | Toxic effect of other metals, intentional self-harm, initial encounter                         |
| T56892D     | Toxic effect of other metals, intentional self-harm, subsequent encounter                      |
| T56892S     | Toxic effect of other metals, intentional self-harm, sequela                                   |
| T5692XA     | Toxic effect of unspecified metal, intentional self-harm, initial encounter                    |
| T5692XD     | Toxic effect of unspecified metal, intentional self-harm, subsequent encounter                 |
| T5692XS     | Toxic effect of unspecified metal, intentional self-harm, sequela                              |
| T570X2A     | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter            |
| T570X2D     | Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter         |
| T570X2S     | Toxic effect of arsenic and its compounds, intentional self-harm, sequela                      |
| T571X2A     | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter         |
| T571X2D     | Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter      |
| T571X2S     | Toxic effect of phosphorus and its compounds, intentional self-harm, sequela                   |
| T572X2A     | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter          |
| T572X2D     | Toxic effect of manganese and its compounds, intentional self-harm, subsequent encounter       |
| T572X2S     | Toxic effect of manganese and its compounds, intentional self-harm, sequela                    |
| T573X2A     | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter                     |
| T573X2D     | Toxic effect of hydrogen cyanide, intentional self-harm, subsequent encounter                  |
| T573X2S     | Toxic effect of hydrogen cyanide, intentional self-harm, sequela                               |
| T578X2A     | Toxic effect of other specified inorganic substances, intentional self-harm, initial encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T578X2D     | Toxic effect of other specified inorganic substances, intentional self-harm, subsequent encounter                               |
| T578X2S     | Toxic effect of other specified inorganic substances, intentional self-harm, sequela  |
| T5792XA     | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter                                       |
| T5792XD     | Toxic effect of unspecified inorganic substance, intentional self-harm, subsequent encounter                                    |
| T5792XS     | Toxic effect of unspecified inorganic substance, intentional self-harm, sequela   |
| T5802XA     | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter                            |
| T5802XD     | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, subsequent encounter                         |
| T5802XS     | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, sequela                                      |
| T5812XA     | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter                                      |
| T5812XD     | Toxic effect of carbon monoxide from utility gas, intentional self-harm, subsequent encounter                                   |
| T5812XS     | Toxic effect of carbon monoxide from utility gas, intentional self-harm, sequela  |
| T582X2A     | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter    |
| T582X2D     | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, subsequent encounter |
| T582X2S     | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, sequela              |
| T588X2A     | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter                                     |
| T588X2D     | Toxic effect of carbon monoxide from other source, intentional self-harm, subsequent encounter                                  |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T588X2S     | Toxic effect of carbon monoxide from other source, intentional self-harm, sequela                    |
| T5892XA     | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter    |
| T5892XD     | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, subsequent encounter |
| T5892XS     | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, sequela              |
| T590X2A     | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter                            |
| T590X2D     | Toxic effect of nitrogen oxides, intentional self-harm, subsequent encounter                         |
| T590X2S     | Toxic effect of nitrogen oxides, intentional self-harm, sequela                                      |
| T591X2A     | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter                             |
| T591X2D     | Toxic effect of sulfur dioxide, intentional self-harm, subsequent encounter                          |
| T591X2S     | Toxic effect of sulfur dioxide, intentional self-harm, sequela                                       |
| T592X2A     | Toxic effect of formaldehyde, intentional self-harm, initial encounter                               |
| T592X2D     | Toxic effect of formaldehyde, intentional self-harm, subsequent encounter                            |
| T592X2S     | Toxic effect of formaldehyde, intentional self-harm, sequela   |
| T593X2A     | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter                           |
| T593X2D     | Toxic effect of lacrimogenic gas, intentional self-harm, subsequent encounter                        |
| T593X2S     | Toxic effect of lacrimogenic gas, intentional self-harm, sequela                                     |
| T594X2A     | Toxic effect of chlorine gas, intentional self-harm, initial encounter                               |
| T594X2D     | Toxic effect of chlorine gas, intentional self-harm, subsequent encounter                            |
| T594X2S     | Toxic effect of chlorine gas, intentional self-harm, sequela   |
| T595X2A     | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter         |
| T595X2D     | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, subsequent encounter      |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T595X2S     | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, sequela                      |
| T596X2A     | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter                              |
| T596X2D     | Toxic effect of hydrogen sulfide, intentional self-harm, subsequent encounter                           |
| T596X2S     | Toxic effect of hydrogen sulfide, intentional self-harm, sequela  |
| T597X2A     | Toxic effect of carbon dioxide, intentional self-harm, initial encounter                                |
| T597X2D     | Toxic effect of carbon dioxide, intentional self-harm, subsequent encounter                             |
| T597X2S     | Toxic effect of carbon dioxide, intentional self-harm, sequela  |
| T59812A     | Toxic effect of smoke, intentional self-harm, initial encounter   |
| T59812D     | Toxic effect of smoke, intentional self-harm, subsequent encounter                                      |
| T59812S     | Toxic effect of smoke, intentional self-harm, sequela   |
| T59892A     | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, initial encounter       |
| T59892D     | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, subsequent encounter    |
| T59892S     | Toxic effect of other specified gases, fumes and vapors, intentional self-harm, sequela                 |
| T5992XA     | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter           |
| T5992XD     | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, subsequent encounter        |
| T5992XS     | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, sequela                     |
| T600X2A     | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter    |
| T600X2D     | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, subsequent encounter |
| T600X2S     | Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, sequela              |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T601X2A     | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter     |
| T601X2D     | Toxic effect of halogenated insecticides, intentional self-harm, subsequent encounter  |
| T601X2S     | Toxic effect of halogenated insecticides, intentional self-harm, sequela               |
| T601X3A     | Toxic effect of halogenated insecticides, assault, initial encounter                   |
| T602X2A     | Toxic effect of other insecticides, intentional self-harm, initial encounter           |
| T602X2D     | Toxic effect of other insecticides, intentional self-harm, subsequent encounter        |
| T602X2S     | Toxic effect of other insecticides, intentional self-harm, sequela                     |
| T603X2A     | Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter    |
| T603X2D     | Toxic effect of herbicides and fungicides, intentional self-harm, subsequent encounter |
| T603X2S     | Toxic effect of herbicides and fungicides, intentional self-harm, sequela              |
| T604X2A     | Toxic effect of rodenticides, intentional self-harm, initial encounter                 |
| T604X2D     | Toxic effect of rodenticides, intentional self-harm, subsequent encounter              |
| T604X2S     | Toxic effect of rodenticides, intentional self-harm, sequela                           |
| T608X2A     | Toxic effect of other pesticides, intentional self-harm, initial encounter             |
| T608X2D     | Toxic effect of other pesticides, intentional self-harm, subsequent encounter          |
| T608X2S     | Toxic effect of other pesticides, intentional self-harm, sequela                       |
| T6092XA     | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter        |
| T6092XD     | Toxic effect of unspecified pesticide, intentional self-harm, subsequent encounter     |
| T6092XS     | Toxic effect of unspecified pesticide, intentional self-harm, sequela                  |
| T6102XA     | Ciguatera fish poisoning, intentional self-harm, initial encounter                     |
| T6102XD     | Ciguatera fish poisoning, intentional self-harm, subsequent encounter                  |
| T6102XS     | Ciguatera fish poisoning, intentional self-harm, sequela                               |
| T6112XA     | Scombroid fish poisoning, intentional self-harm, initial encounter                     |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T6112XD     | Scombroid fish poisoning, intentional self-harm, subsequent encounter                           |
| T6112XS     | Scombroid fish poisoning, intentional self-harm, sequela  |
| T61772A     | Other fish poisoning, intentional self-harm, initial encounter                                  |
| T61772D     | Other fish poisoning, intentional self-harm, subsequent encounter                               |
| T61772S     | Other fish poisoning, intentional self-harm, sequela  |
| T61782A     | Other shellfish poisoning, intentional self-harm, initial encounter                             |
| T61782D     | Other shellfish poisoning, intentional self-harm, subsequent encounter                          |
| T61782S     | Other shellfish poisoning, intentional self-harm, sequela                                       |
| T618X2A     | Toxic effect of other seafood, intentional self-harm, initial encounter                         |
| T618X2D     | Toxic effect of other seafood, intentional self-harm, subsequent encounter                      |
| T618X2S     | Toxic effect of other seafood, intentional self-harm, sequela                                   |
| T6192XA     | Toxic effect of unspecified seafood, intentional self-harm, initial encounter                   |
| T6192XD     | Toxic effect of unspecified seafood, intentional self-harm, subsequent encounter                |
| T6192XS     | Toxic effect of unspecified seafood, intentional self-harm, sequela                             |
| T620X2A     | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter                    |
| T620X2D     | Toxic effect of ingested mushrooms, intentional self-harm, subsequent encounter                 |
| T620X2S     | Toxic effect of ingested mushrooms, intentional self-harm, sequela                              |
| T621X2A     | Toxic effect of ingested berries, intentional self-harm, initial encounter                      |
| T621X2D     | Toxic effect of ingested berries, intentional self-harm, subsequent encounter                   |
| T621X2S     | Toxic effect of ingested berries, intentional self-harm, sequela                                |
| T622X2A     | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, initial encounter    |
| T622X2D     | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, subsequent encounter |
| T622X2S     | Toxic effect of other ingested (parts of) plant(s), intentional self-harm, sequela              |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T628X2A     | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter    |
| T628X2D     | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, subsequent encounter |
| T628X2S     | Toxic effect of other specified noxious substances eaten as food, intentional self-harm, sequela              |
| T6292XA     | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter         |
| T6292XD     | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, subsequent encounter      |
| T6292XS     | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, sequela                   |
| T63002A     | Toxic effect of unspecified snake venom, intentional self-harm, initial encounter                             |
| T63002D     | Toxic effect of unspecified snake venom, intentional self-harm, subsequent encounter                          |
| T63002S     | Toxic effect of unspecified snake venom, intentional self-harm, sequela                                       |
| T63012A     | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter                                   |
| T63012D     | Toxic effect of rattlesnake venom, intentional self-harm, subsequent encounter                                |
| T63012S     | Toxic effect of rattlesnake venom, intentional self-harm, sequela   |
| T63022A     | Toxic effect of coral snake venom, intentional self-harm, initial encounter                                   |
| T63022D     | Toxic effect of coral snake venom, intentional self-harm, subsequent encounter                                |
| T63022S     | Toxic effect of coral snake venom, intentional self-harm, sequela   |
| T63032A     | Toxic effect of taipan venom, intentional self-harm, initial encounter  |
| T63032D     | Toxic effect of taipan venom, intentional self-harm, subsequent encounter                                     |
| T63032S     | Toxic effect of taipan venom, intentional self-harm, sequela  |
| T63042A     | Toxic effect of cobra venom, intentional self-harm, initial encounter   |
| T63042D     | Toxic effect of cobra venom, intentional self-harm, subsequent encounter                                      |
| T63042S     | Toxic effect of cobra venom, intentional self-harm, sequela   |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T63062A     | Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter    |
| T63062D     | Toxic effect of venom of other North and South American snake, intentional self-harm, subsequent encounter |
| T63062S     | Toxic effect of venom of other North and South American snake, intentional self-harm, sequela              |
| T63072A     | Toxic effect of venom of other Australian snake, intentional self-harm, initial encounter                  |
| T63072D     | Toxic effect of venom of other Australian snake, intentional self-harm, subsequent encounter               |
| T63072S     | Toxic effect of venom of other Australian snake, intentional self-harm, sequela                            |
| T63082A     | Toxic effect of venom of other African and Asian snake, intentional self-harm, initial encounter           |
| T63082D     | Toxic effect of venom of other African and Asian snake, intentional self-harm, subsequent encounter        |
| T63082S     | Toxic effect of venom of other African and Asian snake, intentional self-harm, sequela                     |
| T63092A     | Toxic effect of venom of other snake, intentional self-harm, initial encounter                             |
| T63092D     | Toxic effect of venom of other snake, intentional self-harm, subsequent encounter                          |
| T63092S     | Toxic effect of venom of other snake, intentional self-harm, sequela                                       |
| T63112A     | Toxic effect of venom of gila monster, intentional self-harm, initial encounter                            |
| T63112D     | Toxic effect of venom of gila monster, intentional self-harm, subsequent encounter                         |
| T63112S     | Toxic effect of venom of gila monster, intentional self-harm, sequela                                      |
| T63122A     | Toxic effect of venom of other venomous lizard, intentional self-harm, initial encounter                   |
| T63122D     | Toxic effect of venom of other venomous lizard, intentional self-harm, subsequent encounter                |



Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T63122S     | Toxic effect of venom of other venomous lizard, intentional self-harm, sequela             |
| T63192A     | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter          |
| T63192D     | Toxic effect of venom of other reptiles, intentional self-harm, subsequent encounter       |
| T63192S     | Toxic effect of venom of other reptiles, intentional self-harm, sequela                    |
| T632X2A     | Toxic effect of venom of scorpion, intentional self-harm, initial encounter                |
| T632X2D     | Toxic effect of venom of scorpion, intentional self-harm, subsequent encounter             |
| T632X2S     | Toxic effect of venom of scorpion, intentional self-harm, sequela                          |
| T63302A     | Toxic effect of unspecified spider venom, intentional self-harm, initial encounter         |
| T63302D     | Toxic effect of unspecified spider venom, intentional self-harm, subsequent encounter      |
| T63302S     | Toxic effect of unspecified spider venom, intentional self-harm, sequela                   |
| T63312A     | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter      |
| T63312D     | Toxic effect of venom of black widow spider, intentional self-harm, subsequent encounter   |
| T63312S     | Toxic effect of venom of black widow spider, intentional self-harm, sequela                |
| T63322A     | Toxic effect of venom of tarantula, intentional self-harm, initial encounter               |
| T63322D     | Toxic effect of venom of tarantula, intentional self-harm, subsequent encounter            |
| T63322S     | Toxic effect of venom of tarantula, intentional self-harm, sequela                         |
| T63332A     | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter    |
| T63332D     | Toxic effect of venom of brown recluse spider, intentional self-harm, subsequent encounter |
| T63332S     | Toxic effect of venom of brown recluse spider, intentional self-harm, sequela              |
| T63392A     | Toxic effect of venom of other spider, intentional self-harm, initial encounter            |
| T63392D     | Toxic effect of venom of other spider, intentional self-harm, subsequent encounter         |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T63392S     | Toxic effect of venom of other spider, intentional self-harm, sequela                                    |
| T63412A     | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, initial encounter    |
| T63412D     | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, subsequent encounter |
| T63412S     | Toxic effect of venom of centipedes and venomous millipedes, intentional self-harm, sequela              |
| T63422A     | Toxic effect of venom of ants, intentional self-harm, initial encounter                                  |
| T63422D     | Toxic effect of venom of ants, intentional self-harm, subsequent encounter                               |
| T63422S     | Toxic effect of venom of ants, intentional self-harm, sequela  |
| T63432A     | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter                          |
| T63432D     | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter                       |
| T63432S     | Toxic effect of venom of caterpillars, intentional self-harm, sequela                                    |
| T63442A     | Toxic effect of venom of bees, intentional self-harm, initial encounter                                  |
| T63442D     | Toxic effect of venom of bees, intentional self-harm, subsequent encounter                               |
| T63442S     | Toxic effect of venom of bees, intentional self-harm, sequela  |
| T63452A     | Toxic effect of venom of hornets, intentional self-harm, initial encounter                               |
| T63452D     | Toxic effect of venom of hornets, intentional self-harm, subsequent encounter                            |
| T63452S     | Toxic effect of venom of hornets, intentional self-harm, sequela   |
| T63462A     | Toxic effect of venom of wasps, intentional self-harm, initial encounter                                 |
| T63462D     | Toxic effect of venom of wasps, intentional self-harm, subsequent encounter                              |
| T63462S     | Toxic effect of venom of wasps, intentional self-harm, sequela   |
| T63482A     | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter                       |
| T63482D     | Toxic effect of venom of other arthropod, intentional self-harm, subsequent encounter                    |
| T63482S     | Toxic effect of venom of other arthropod, intentional self-harm, sequela                                 |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T63512A     | Toxic effect of contact with stingray, intentional self-harm, initial encounter                         |
| T63512D     | Toxic effect of contact with stingray, intentional self-harm, subsequent encounter                      |
| T63512S     | Toxic effect of contact with stingray, intentional self-harm, sequela                                   |
| T63592A     | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter              |
| T63592D     | Toxic effect of contact with other venomous fish, intentional self-harm, subsequent encounter           |
| T63592S     | Toxic effect of contact with other venomous fish, intentional self-harm, sequela                        |
| T63612A     | Toxic effect of contact with Portugese Man-o-war, intentional self-harm, initial encounter              |
| T63612D     | Toxic effect of contact with Portugese Man-o-war, intentional self-harm, subsequent encounter           |
| T63612S     | Toxic effect of contact with Portugese Man-o-war, intentional self-harm, sequela                        |
| T63622A     | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter                  |
| T63622D     | Toxic effect of contact with other jellyfish, intentional self-harm, subsequent encounter               |
| T63622S     | Toxic effect of contact with other jellyfish, intentional self-harm, sequela                            |
| T63632A     | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter                      |
| T63632D     | Toxic effect of contact with sea anemone, intentional self-harm, subsequent encounter                   |
| T63632S     | Toxic effect of contact with sea anemone, intentional self-harm, sequela                                |
| T63692A     | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter    |
| T63692D     | Toxic effect of contact with other venomous marine animals, intentional self-harm, subsequent encounter |
| T63692S     | Toxic effect of contact with other venomous marine animals, intentional self-harm, sequela              |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T63712A     | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter       |
| T63712D     | Toxic effect of contact with venomous marine plant, intentional self-harm, subsequent encounter    |
| T63712S     | Toxic effect of contact with venomous marine plant, intentional self-harm, sequela                 |
| T63792A     | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter        |
| T63792D     | Toxic effect of contact with other venomous plant, intentional self-harm, subsequent encounter     |
| T63792S     | Toxic effect of contact with other venomous plant, intentional self-harm, sequela                  |
| T63812A     | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter               |
| T63812D     | Toxic effect of contact with venomous frog, intentional self-harm, subsequent encounter            |
| T63812S     | Toxic effect of contact with venomous frog, intentional self-harm, sequela                         |
| T63822A     | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter               |
| T63822D     | Toxic effect of contact with venomous toad, intentional self-harm, subsequent encounter            |
| T63822S     | Toxic effect of contact with venomous toad, intentional self-harm, sequela                         |
| T63832A     | Toxic effect of contact with other venomous amphibian, intentional self-harm, initial encounter    |
| T63832D     | Toxic effect of contact with other venomous amphibian, intentional self-harm, subsequent encounter |
| T63832S     | Toxic effect of contact with other venomous amphibian, intentional self-harm, sequela              |
| T63892A     | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter      |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T63892D     | Toxic effect of contact with other venomous animals, intentional self-harm, subsequent encounter      |
| T63892S     | Toxic effect of contact with other venomous animals, intentional self-harm, sequela                   |
| T6392XA     | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter    |
| T6392XD     | Toxic effect of contact with unspecified venomous animal, intentional self-harm, subsequent encounter |
| T6392XS     | Toxic effect of contact with unspecified venomous animal, intentional self-harm, sequela              |
| T6402XA     | Toxic effect of aflatoxin, intentional self-harm, initial encounter                                   |
| T6402XD     | Toxic effect of aflatoxin, intentional self-harm, subsequent encounter                                |
| T6402XS     | Toxic effect of aflatoxin, intentional self-harm, sequela   |
| T6482XA     | Toxic effect of other mycotoxin food contaminants, intentional self-harm, initial encounter           |
| T6482XD     | Toxic effect of other mycotoxin food contaminants, intentional self-harm, subsequent encounter        |
| T6482XS     | Toxic effect of other mycotoxin food contaminants, intentional self-harm, sequela                     |
| T650X2A     | Toxic effect of cyanides, intentional self-harm, initial encounter                                    |
| T650X2D     | Toxic effect of cyanides, intentional self-harm, subsequent encounter                                 |
| T650X2S     | Toxic effect of cyanides, intentional self-harm, sequela  |
| T651X2A     | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter                    |
| T651X2D     | Toxic effect of strychnine and its salts, intentional self-harm, subsequent encounter                 |
| T651X2S     | Toxic effect of strychnine and its salts, intentional self-harm, sequela                              |
| T65212A     | Toxic effect of chewing tobacco, intentional self-harm, initial encounter                             |
| T65212D     | Toxic effect of chewing tobacco, intentional self-harm, subsequent encounter                          |

## Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>   |
|-------------|--|
| T65212S     | Toxic effect of chewing tobacco, intentional self-harm, sequela  |
| T65222A     | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter   |
| T65222D     | Toxic effect of tobacco cigarettes, intentional self-harm, subsequent encounter  |
| T65222S     | Toxic effect of tobacco cigarettes, intentional self-harm, sequela   |
| T65292A     | Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter   |
| T65292D     | Toxic effect of other tobacco and nicotine, intentional self-harm, subsequent encounter  |
| T65292S     | Toxic effect of other tobacco and nicotine, intentional self-harm, sequela   |
| T653X2A     | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter    |
| T653X2D     | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, subsequent encounter |
| T653X2S     | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, sequela              |
| T654X2A     | Toxic effect of carbon disulfide, intentional self-harm, initial encounter   |
| T654X2D     | Toxic effect of carbon disulfide, intentional self-harm, subsequent encounter  |
| T654X2S     | Toxic effect of carbon disulfide, intentional self-harm, sequela   |
| T655X2A     | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter                        |
| T655X2D     | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter                     |
| T655X2S     | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela                                  |
| T656X2A     | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter                              |
| T656X2D     | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, subsequent encounter                           |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Poisoning by Toxic Effect</b>  |
|-------------|---|
| T656X2S     | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, sequela   |
| T65812A     | Toxic effect of latex, intentional self-harm, initial encounter                             |
| T65812D     | Toxic effect of latex, intentional self-harm, subsequent encounter                          |
| T65812S     | Toxic effect of latex, intentional self-harm, sequela                                       |
| T65822A     | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter    |
| T65822D     | Toxic effect of harmful algae and algae toxins, intentional self-harm, subsequent encounter |
| T65822S     | Toxic effect of harmful algae and algae toxins, intentional self-harm, sequela              |
| T65832A     | Toxic effect of fiberglass, intentional self-harm, initial encounter                        |
| T65832D     | Toxic effect of fiberglass, intentional self-harm, subsequent encounter                     |
| T65832S     | Toxic effect of fiberglass, intentional self-harm, sequela                                  |
| T65892A     | Toxic effect of other specified substances, intentional self-harm, initial encounter        |
| T65892D     | Toxic effect of other specified substances, intentional self-harm, subsequent encounter     |
| T65892S     | Toxic effect of other specified substances, intentional self-harm, sequela                  |
| T6592XA     | Toxic effect of unspecified substance, intentional self-harm, initial encounter             |
| T6592XD     | Toxic effect of unspecified substance, intentional self-harm, subsequent encounter          |
| T6592XS     | Toxic effect of unspecified substance, intentional self-harm, sequela                       |

***Intentional Self-Inflicted Injury.*** ICD-10-CM codes related to self-inflicted injuries that do not involve poisoning are coded to the specific injury followed by an external cause of injury code (if reported) (codes X71-X83). Those codes are listed in Table 3 below.

**Table 3. Suicide Attempt by Self-Inflicted Injury Codes**

| <b>Code</b> | <b>Self-Inflicted Injury</b>   |
|-------------|--|
| X710XXA     | Intentional self-harm by drowning and submersion while in bathtub, initial encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Self-Inflicted Injury</b>   |
|-------------|--|
| X710XXD     | Intentional self-harm by drowning and submersion while in bathtub, subsequent encounter              |
| X710XXS     | Intentional self-harm by drowning and submersion while in bathtub, sequela                           |
| X711XXA     | Intentional self-harm by drowning and submersion while in swimming pool, initial encounter           |
| X711XXD     | Intentional self-harm by drowning and submersion while in swimming pool, subsequent encounter        |
| X711XXS     | Intentional self-harm by drowning and submersion while in swimming pool, sequela                     |
| X712XXA     | Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter    |
| X712XXD     | Intentional self-harm by drowning and submersion after jump into swimming pool, subsequent encounter |
| X712XXS     | Intentional self-harm by drowning and submersion after jump into swimming pool, sequela              |
| X713XXA     | Intentional self-harm by drowning and submersion in natural water, initial encounter                 |
| X713XXD     | Intentional self-harm by drowning and submersion in natural water, subsequent encounter              |
| X713XXS     | Intentional self-harm by drowning and submersion in natural water, sequela                           |
| X718XXA     | Other intentional self-harm by drowning and submersion, initial encounter                            |
| X718XXD     | Other intentional self-harm by drowning and submersion, subsequent encounter                         |
| X718XXS     | Other intentional self-harm by drowning and submersion, sequela                                      |
| X719XXA     | Intentional self-harm by drowning and submersion, unspecified, initial encounter                     |
| X719XXD     | Intentional self-harm by drowning and submersion, unspecified, subsequent encounter                  |
| X719XXS     | Intentional self-harm by drowning and submersion, unspecified, sequela                               |
| X72XXXA     | Intentional self-harm by handgun discharge, initial encounter  |
| X72XXXD     | Intentional self-harm by handgun discharge, subsequent encounter                                     |



Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Self-Inflicted Injury</b>   |
|-------------|--|
| X72XXXS     | Intentional self-harm by handgun discharge, sequela                                  |
| X730XXA     | Intentional self-harm by shotgun discharge, initial encounter                        |
| X730XXD     | Intentional self-harm by shotgun discharge, subsequent encounter                     |
| X730XXS     | Intentional self-harm by shotgun discharge, sequela                                  |
| X731XXA     | Intentional self-harm by hunting rifle discharge, initial encounter                  |
| X731XXD     | Intentional self-harm by hunting rifle discharge, subsequent encounter               |
| X731XXS     | Intentional self-harm by hunting rifle discharge, sequela                            |
| X732XXA     | Intentional self-harm by machine gun discharge, initial encounter                    |
| X732XXD     | Intentional self-harm by machine gun discharge, subsequent encounter                 |
| X732XXS     | Intentional self-harm by machine gun discharge, sequela                              |
| X738XXA     | Intentional self-harm by other larger firearm discharge, initial encounter           |
| X738XXD     | Intentional self-harm by other larger firearm discharge, subsequent encounter        |
| X738XXS     | Intentional self-harm by other larger firearm discharge, sequela                     |
| X739XXA     | Intentional self-harm by unspecified larger firearm discharge, initial encounter     |
| X739XXD     | Intentional self-harm by unspecified larger firearm discharge, subsequent encounter  |
| X739XXS     | Intentional self-harm by unspecified larger firearm discharge, sequela               |
| X7401XA     | Intentional self-harm by airgun, initial encounter                                   |
| X7401XD     | Intentional self-harm by airgun, subsequent encounter                                |
| X7401XS     | Intentional self-harm by airgun, sequela   |
| X7402XA     | Intentional self-harm by paintball gun, initial encounter                            |
| X7402XD     | Intentional self-harm by paintball gun, subsequent encounter                         |
| X7402XS     | Intentional self-harm by paintball gun, sequela                                      |
| X7409XA     | Intentional self-harm by other gas, air or spring-operated gun, initial encounter    |
| X7409XD     | Intentional self-harm by other gas, air or spring-operated gun, subsequent encounter |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Self-Inflicted Injury</b>   |
|-------------|--|
| X7409XS     | Intentional self-harm by other gas, air or spring-operated gun, sequela      |
| X748XXA     | Intentional self-harm by other firearm discharge, initial encounter          |
| X748XXD     | Intentional self-harm by other firearm discharge, subsequent encounter       |
| X748XXS     | Intentional self-harm by other firearm discharge, sequela                    |
| X749XXA     | Intentional self-harm by unspecified firearm discharge, initial encounter    |
| X749XXD     | Intentional self-harm by unspecified firearm discharge, subsequent encounter |
| X749XXS     | Intentional self-harm by unspecified firearm discharge, sequela              |
| X75XXXA     | Intentional self-harm by explosive material, initial encounter               |
| X75XXXD     | Intentional self-harm by explosive material, subsequent encounter            |
| X75XXXS     | Intentional self-harm by explosive material, sequela                         |
| X76XXXA     | Intentional self-harm by smoke, fire and flames, initial encounter           |
| X76XXXD     | Intentional self-harm by smoke, fire and flames, subsequent encounter        |
| X76XXXS     | Intentional self-harm by smoke, fire and flames, sequela                     |
| X770XXA     | Intentional self-harm by steam or hot vapors, initial encounter              |
| X770XXD     | Intentional self-harm by steam or hot vapors, subsequent encounter           |
| X770XXS     | Intentional self-harm by steam or hot vapors, sequela                        |
| X771XXA     | Intentional self-harm by hot tap water, initial encounter                    |
| X771XXD     | Intentional self-harm by hot tap water, subsequent encounter                 |
| X771XXS     | Intentional self-harm by hot tap water, sequela                              |
| X772XXA     | Intentional self-harm by other hot fluids, initial encounter                 |
| X772XXD     | Intentional self-harm by other hot fluids, subsequent encounter              |
| X772XXS     | Intentional self-harm by other hot fluids, sequela                           |
| X773XXA     | Intentional self-harm by hot household appliances, initial encounter         |
| X773XXD     | Intentional self-harm by hot household appliances, subsequent encounter      |
| X773XXS     | Intentional self-harm by hot household appliances, sequela                   |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Self-Inflicted Injury</b>  |
|-------------|---|
| X778XXA     | Intentional self-harm by other hot objects, initial encounter           |
| X778XXD     | Intentional self-harm by other hot objects, subsequent encounter        |
| X778XXS     | Intentional self-harm by other hot objects, sequela                     |
| X779XXA     | Intentional self-harm by unspecified hot objects, initial encounter     |
| X779XXD     | Intentional self-harm by unspecified hot objects, subsequent encounter  |
| X779XXS     | Intentional self-harm by unspecified hot objects, sequela               |
| X780XXA     | Intentional self-harm by sharp glass, initial encounter                 |
| X780XXD     | Intentional self-harm by sharp glass, subsequent encounter              |
| X780XXS     | Intentional self-harm by sharp glass, sequela                           |
| X781XXA     | Intentional self-harm by knife, initial encounter                       |
| X781XXD     | Intentional self-harm by knife, subsequent encounter                    |
| X781XXS     | Intentional self-harm by knife, sequela                                 |
| X782XXA     | Intentional self-harm by sword or dagger, initial encounter             |
| X782XXD     | Intentional self-harm by sword or dagger, subsequent encounter          |
| X782XXS     | Intentional self-harm by sword or dagger, sequela                       |
| X788XXA     | Intentional self-harm by other sharp object, initial encounter          |
| X788XXD     | Intentional self-harm by other sharp object, subsequent encounter       |
| X788XXS     | Intentional self-harm by other sharp object, sequela                    |
| X789XXA     | Intentional self-harm by unspecified sharp object, initial encounter    |
| X789XXD     | Intentional self-harm by unspecified sharp object, subsequent encounter |
| X789XXS     | Intentional self-harm by unspecified sharp object, sequela              |
| X79XXXA     | Intentional self-harm by blunt object, initial encounter                |
| X79XXXD     | Intentional self-harm by blunt object, subsequent encounter             |
| X79XXXS     | Intentional self-harm by blunt object, sequela                          |
| X80XXXA     | Intentional self-harm by jumping from a high place, initial encounter   |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Self-Inflicted Injury</b>  |
|-------------|---|
| X80XXXD     | Intentional self-harm by jumping from a high place, subsequent encounter                        |
| X80XXXS     | Intentional self-harm by jumping from a high place, sequela                                     |
| X810XXA     | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter          |
| X810XXD     | Intentional self-harm by jumping or lying in front of motor vehicle, subsequent encounter       |
| X810XXS     | Intentional self-harm by jumping or lying in front of motor vehicle, sequela                    |
| X811XXA     | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter         |
| X811XXD     | Intentional self-harm by jumping or lying in front of (subway) train, subsequent encounter      |
| X811XXS     | Intentional self-harm by jumping or lying in front of (subway) train, sequela                   |
| X818XXA     | Intentional self-harm by jumping or lying in front of other moving object, initial encounter    |
| X818XXD     | Intentional self-harm by jumping or lying in front of other moving object, subsequent encounter |
| X818XXS     | Intentional self-harm by jumping or lying in front of other moving object, sequela              |
| X820XXA     | Intentional collision of motor vehicle with other motor vehicle, initial encounter              |
| X820XXD     | Intentional collision of motor vehicle with other motor vehicle, subsequent encounter           |
| X820XXS     | Intentional collision of motor vehicle with other motor vehicle, sequela                        |
| X821XXA     | Intentional collision of motor vehicle with train, initial encounter                            |
| X821XXD     | Intentional collision of motor vehicle with train, subsequent encounter                         |
| X821XXS     | Intentional collision of motor vehicle with train, sequela                                      |
| X822XXA     | Intentional collision of motor vehicle with tree, initial encounter                             |
| X822XXD     | Intentional collision of motor vehicle with tree, subsequent encounter                          |
| X822XXS     | Intentional collision of motor vehicle with tree, sequela                                       |

Appendix SU-A. ICD-10-CM Codes Relevant to Calculating Suicide Attempts

| <b>Code</b> | <b>Self-Inflicted Injury</b>   |
|-------------|--|
| X828XXA     | Other intentional self-harm by crashing of motor vehicle, initial encounter    |
| X828XXD     | Other intentional self-harm by crashing of motor vehicle, subsequent encounter |
| X828XXS     | Other intentional self-harm by crashing of motor vehicle, sequela              |
| X830XXA     | Intentional self-harm by crashing of aircraft, initial encounter               |
| X830XXD     | Intentional self-harm by crashing of aircraft, subsequent encounter            |
| X830XXS     | Intentional self-harm by crashing of aircraft, sequela                         |
| X831XXA     | Intentional self-harm by electrocution, initial encounter                      |
| X831XXD     | Intentional self-harm by electrocution, subsequent encounter                   |
| X831XXS     | Intentional self-harm by electrocution, sequela                                |
| X832XXA     | Intentional self-harm by exposure to extremes of cold, initial encounter       |
| X832XXD     | Intentional self-harm by exposure to extremes of cold, subsequent encounter    |
| X832XXS     | Intentional self-harm by exposure to extremes of cold, sequela                 |
| X838XXA     | Intentional self-harm by other specified means, initial encounter              |
| X838XXD     | Intentional self-harm by other specified means, subsequent encounter           |
| X838XXS     | Intentional self-harm by other specified means, sequela                        |

***Suicidal Ideation and Suicide Attempt Codes:*** Suicidal ideation is coded as R45851, but that code alone is insufficient to warrant inclusion in the numerator. Suicidal ideation accompanied by a code indicating injury is required for reliance on the ideation code.

The suicide attempt code T1491 is only used if there is no other documentation that identifies a more detailed code.

**Appendix PCR-BH: Plan All-Cause Readmissions Rate**

The number of acute inpatient stays for consumers age 18 and older during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days.

**Table PCR-A: Plan All-Cause Readmissions Rates by Age and Risk Adjustment: Ages 18 to 64**

| Age   | Count of Index Stays (Denominator) (1) | Count of 30-Day Readmissions (Numerator) (2) | Observed Readmissions (Num/Den) (3) | Average Adjusted Probability (4) | Total Variance (5) | O/E Ratio (Observed Readmissions/Average Adjusted Probability) (6) | Lower Confidence Interval (O/E Ratio) | Upper Confidence Interval (O/E Ratio) |
|-------|--|--|-------------------------------------|----------------------------------|--------------------|--|---------------------------------------|---------------------------------------|
| 18-44 |  |  |                                     |                                  |                    |  |                                       |                                       |
| 45-54 |  |  |                                     |                                  |                    |  |                                       |                                       |
| 55-64 |  |  |                                     |                                  |                    |  |                                       |                                       |
| Total |  |  |                                     |                                  |                    |  |                                       |                                       |

Note: This measure requires risk adjustment. However, there are no standardized risk adjustment tables for Medicaid. Therefore, it is suggested that states report the unadjusted total rates for this measure (columns 1, 2, and 3) because Medicaid-specific risk adjustment tables are required to calculate columns 4, 5, 6, and the confidence intervals.

**Table PCR-B. Plan All-Cause Readmissions Rates by Age and Risk Adjustment: Age 65 and Older**

| Age   | Count of Index Stays (Denominator) (1) | Count of 30-Day Readmissions (Numerator) (2) | Observed Readmissions (Num/Den) (3) | Average Adjusted Probability (4) | Total Variance (5) | O/E Ratio (Observed Readmissions/Average Adjusted Probability) (6) | Lower Confidence Interval (O/E Ratio) | Upper Confidence Interval (O/E Ratio) |
|-------|--|--|-------------------------------------|----------------------------------|--------------------|--|---------------------------------------|---------------------------------------|
| 65-74 |  |  |                                     |                                  |                    |  |                                       |                                       |
| 75-84 |  |  |                                     |                                  |                    |  |                                       |                                       |
| 85+   |  |  |                                     |                                  |                    |  |                                       |                                       |

Appendix PCR-BH: Plan All-Cause Readmissions Rate

| Age   | Count of Index Stays (Denominator) (1) | Count of 30-Day Readmissions (Numerator) (2) | Observed Readmissions (Num/Den) (3) | Average Adjusted Probability (4) | Total Variance (5) | O/E Ratio (Observed Readmissions/Average Adjusted Probability) (6) | Lower Confidence Interval (O/E Ratio) | Upper Confidence Interval (O/E Ratio) |
|-------|--|--|-------------------------------------|----------------------------------|--------------------|--|---------------------------------------|---------------------------------------|
| Total |  |  |                                     |                                  |                    |  |                                       |                                       |

Note: This measure requires risk adjustment. However, there are no standardized risk adjustment tables for Medicaid. Therefore, CMS suggests that states report the unadjusted total rates for this measure (columns 1, 2, and 3) because Medicaid-specific risk adjustment tables are required to calculate columns 4, 5, and 6.

## Appendix AMS-BD: Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder

**Table 1. Codes Used to Identify Bipolar I Disorder Diagnosis**

| Category                            | Codes   |
|-------------------------------------|---|
| <b>Bipolar I Disorder Diagnosis</b> | F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78, F31.89, F31.9 |

**Table 2.1. Codes Used to Identify Outpatient Setting Encounter Type**

| Category   | Codes   |
|--|---|
| <b>Current Procedural Terminology (CPT®)</b>             | 98960–98962, 99078, 99201–99205, 99211–99215, 99217–99220, 99241–99245, 99341–99345, 99347–99350, 99385–99387, 99395–99397, 99401–99404, 99411, 99412, 99429, 99510     |
| <b>Healthcare Common Procedure Coding System (HCPCS)</b> | G0155, G0176, G0177, G0409–G0411, G0463, H0002, H0004, H0031, H0034–H0037, H0039, H0040, H2000, H2001, H2010–H2020, M0064, S0201, S9480, S9484, S9485, T1015            |
| <b>Uniform Billing (UB) UB-92 revenue</b>                | 0510, 0511, 0513, 0516–0517, 0519–0523, 0526–0529, 0770, 0771, 0779, 0900–0905, 0907, 0911–0917, 0919, 0982, 0983   |
| <b>CPT</b>   | 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90863, 90867–90870, 90875, 90876, 90880, 99221–99223, 99231–99233, 99238, 99239, 99251–99255, 99291 |
| <b>With Place of Service (POS)</b>                       | 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24, 33, 49, 50, 52, 53, 71, 72  |



**Table 2.2. Codes Used to Identify ED Setting Encounter Type**

| Category                           | Codes   |
|------------------------------------|---|
| <b>CPT</b>                         | 99281–99285   |
| <b>UB-92 revenue</b>               | 0450, 0451, 0452, 0456, 0459, 0981  |
| <b>CPT</b>                         | 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90863, 90867–90870, 90875, 90876, 99291 |
| <b>With Place of Service (POS)</b> | 23  |

**Table 2.3. Codes Used to Identify Nonacute Inpatient Setting Encounter Type**

| Category             | Codes  |
|----------------------|--|
| <b>CPT</b>           | 99304–99310, 99315, 99316, 99318, 99324–99328, 99334–99337   |
| <b>HCPCS</b>         | H0017–H0019, T2048   |
| <b>UB-92 revenue</b> | 0118, 0128, 0138, 0148, 0158, 0190–0194, 0199, 0524, 0525, 0550–0552, 0559, 0660–0663, 0669, 1000, 1001, 1003–1005 |
| <b>CPT</b>           | 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90863, 90867–90870, 90875, 90876, 99291        |
| <b>WITH POS</b>      | 31, 32, 56   |

**Table 2.4. Codes Used to Identify Acute Inpatient Setting Encounter Type**

| Category             | Codes  |
|----------------------|--|
| <b>UB-92 revenue</b> | 0100, 0101, 0110–0114, 0119–0124, 0129–0134, 0139–0144, 0149–0154, 0159, 0160, 0164, 0167, 0169, 0200–0204, 0206–0209, 0210–0214, 0219, 0720–0724, 0729, 0987    |
| <b>CPT</b>           | 90791, 90792, 90832–90834, 90836–90840, 90845, 90847, 90849, 90853, 90863, 90867–90870, 90875, 90876, 99221–99223, 99231–99233, 99238, 99239, 99251–99255, 99291 |

| <b>Category</b> | <b>Codes</b> |
|-----------------|--------------|
| <b>WITH POS</b> | 21, 51       |

The following are the mood stabilizer medications by class for the denominator. The route of administration includes all oral formulations of the medications listed below.

**Table 3. Mood Stabilizer Medications**

| <b>Class</b>                                | <b>Medication</b>  |
|---|--|
| <b>Anticonvulsants</b>                      | carbamazepine<br>divalproex sodium<br>lamotrigine<br>valproic acid   |
| <b>Atypical Antipsychotics</b>              | aripiprazole<br>asenapine<br>clozapine<br>iloperidone<br>lurasidone<br>olanzapine<br>paliperidone<br>quetiapine<br>risperidone<br>ziprasidone                                      |
| <b>Phenothiazine/Related Antipsychotics</b> | chlorpromazine<br>fluphenazine<br>haloperidol<br>loxapine succinate<br>molindone<br>perphenazine<br>pimozide<br>prochlorperazine<br>thioridazine<br>thiothixene<br>trifluoperazine |
| <b>Other Antipsychotics</b>                 | olanzapine-fluoxetine  |

| <b>Class</b>         | <b>Medication</b>                    |
|----------------------|--------------------------------------|
| <b>Lithium Salts</b> | lithium carbonate<br>lithium citrate |

**Note:** Active ingredients listed above are limited to oral, buccal, sublingual, and translingual formulations only. Obsolete drug products are excluded from National Drug Codes (NDCs) with an inactive date more than 3 years prior to the beginning of the measurement period or look-back period, if applicable.

The following are the long-acting (depot) injectable antipsychotic medications by class for the denominator. The route of administration includes all injectable and intramuscular formulations of the medications listed below.

**Table 4: Long-Acting Injectable Antipsychotic Medications**

| <b>Class</b>  | <b>Medication</b>   |
|---|---|
| <b>Typical Antipsychotic Medications</b>                        | fluphenazine decanoate (J2680)<br>haloperidol decanoate (J1631)   |
| <b>Atypical Antipsychotic Medications</b>                       | aripiprazole (J0401)<br>olanzapine pamoate (J2358)<br>paliperidone palmitate (J2426)<br>risperidone microspheres (J2794)  |
| <b>Long-Acting (Depot) Injectable Antipsychotic Medications</b> | fluphenazine decanoate (J2680) – 28 days' supply<br>haloperidol decanoate (J1631) – 28 days' supply<br>aripiprazole (J0401) – 28 days' supply<br>olanzapine pamoate (J2358) – 28 days' supply<br>paliperidone palmitate (J2426) – 28 days' supply<br>risperidone microspheres (J2794) – 14 days' supply |

**Note:** Since the days' supply variable is not reliable for long-acting injections in administrative data, the days' supply is imputed for the long-acting (depot) injectable antipsychotic medications listed above.

## Appendix SAA-BH: Adherence to Antipsychotics for Individuals with Schizophrenia

**Table SAA-A: Antipsychotic Medications**

| Description                               | Prescription  | Covered Days |
|---|---|--------------|
| Miscellaneous antipsychotic agents (oral) | Aripiprazole<br>Asenapine<br>Brexpiprazole<br>Clozapine<br>Haloperidol<br>Iloperidone<br>Loxapine<br>Lurasidone<br>Molindone<br>Olanzapine<br>Paliperidone<br>Pimozide<br>Quetiapine<br>Quetiapine fumarate<br>Risperidone<br>Ziprasidone |              |
| Phenothiazine antipsychotics (oral)       | Chlorpromazine<br>Fluphenazine<br>Perphenazine<br>Perphenazine-amitriptyline<br>Prochloroperazine<br>Thioridazine<br>Trifluoperazine  |              |
| Psychotherapeutic combinations (oral)     | Fluoxetine-olanzapine   |              |
| Thioxanthenes (oral)                      | Thiothixene   |              |

Appendix SAA-BH: Adherence to Antipsychotics for Individuals with Schizophrenia

| Description            | Prescription   | Covered Days   |
|------------------------|--|----------------|
| Long-acting injections | Aripiprazole<br>Fluphenazine decanoate<br>Haloperidol decanoate<br>Olanzapine.<br>Paliperidone palmitate | 28 days supply |
|                        | Risperidone  | 14 days supply |

**Note:** NCQA's National Drug Code (NDC) current list of antipsychotic medications can be found at: [HEDIS NDC page](#).

Appendix ADD-BH: Follow-Up Care for Children Prescribed Attention-Deficit Hyperactivity Disorder (ADHD) Medication

Please see NCQA Notice of Copyright and Disclaimers in front matter to Volume 1 of this manual.

**Appendix ADD-BH: Follow-Up Care for Children Prescribed Attention-Deficit Hyperactivity Disorder (ADHD) Medication**

**Table ADD.A. ADHD Medications**

| <b>Description</b>             | <b>Prescription</b>  |
|--------------------------------|--|
| CNS stimulants                 | Amphetamine-dextroamphetamine<br>Dexmethylphenidate<br>Dextroamphetamine<br>Lisdexamfetamine<br>Methamphetamine<br>Methylphenidate |
| Alpha-2 receptor agonists      | Clonidine<br>Guanfacine  |
| Miscellaneous ADHD medications | Atomoxetine  |

*Note:* NCQA's National Drug Code (NDC) current list of ADHD medications can be found at: [HEDIS NDC page](#)

**Appendix AMM-BH: Antidepressant Medication Management****Table AMM-C: Antidepressant Medications**

| <b>Description</b>               | <b>Prescription</b>   |
|----------------------------------|---|
| Miscellaneous antidepressants    | Bupropion<br>Vilazodone<br>Vortioxetine   |
| Monoamine oxidase inhibitors     | Isocarboxazid<br>Phenelzine<br>Selegiline<br>Tranlycypromine                          |
| Phenylpiperazine antidepressants | Nefazodone<br>Trazodone   |
| Psychotherapeutic combinations   | Amitriptyline-chlordiazepoxide<br>Amitriptyline-perphenazine<br>Fluoxetine-olanzapine |
| SSNRI antidepressants            | Desvenlafaxine<br>Duloxetine<br>Levomilnacipran<br>Venlafaxine                        |
| SSRI antidepressants             | Citalopram<br>Escitalopram<br>Fluoxetine<br>Fluvoxamine<br>Paroxetine<br>Sertraline   |
| Tetracyclic antidepressants      | Maprotiline<br>Mirtazapine  |

Appendix AMM-BH: Antidepressant Medication Management

Please see NCQA Notice of Copyright and Disclaimers in front matter to Volume 1 of this manual.

| <b>Description</b>        | <b>Prescription</b>  |
|---------------------------|--|
| Tricyclic antidepressants | Amitriptyline<br>Amoxapine<br>Clomipramine<br>Desipramine<br>Doxepin (>6 mg)<br>Imipramine<br>Nortriptyline<br>Protriptyline<br>Trimipramine |

**Note:** NCQA's National Drug Code (NDC) current list of antidepressant medications can be found at: [HEDIS NDC page](#)